WEBVTT
00:00.031 --> 00:01.413
[SPEAKER_01]: health is very complex.
00:01.593 --> 00:04.957
[SPEAKER_01]: Our body have so many things that's happening all like once.
00:05.037 --> 00:07.860
[SPEAKER_01]: We're dealing with a web, the web of biology.
00:08.080 --> 00:14.047
[SPEAKER_01]: The stem cells can go in and provide some fundamental shifts, but it's not covering all ground.
00:14.347 --> 00:22.577
[SPEAKER_01]: I think it would be naive to think just because stem cell therapy is amazing that I can just give you one treatment and then expect everybody to do amazingly well.
00:22.617 --> 00:29.565
[SPEAKER_01]: The person could be deficient in amino acids and minerals
00:29.545 --> 00:32.388
[SPEAKER_01]: I always try to give people a realistic expectation.
00:32.609 --> 00:35.632
[SPEAKER_01]: I'm hoping for miracles, but I'm not expecting miracles.
00:35.952 --> 00:40.217
[SPEAKER_01]: And then there may be a regiment that's needed, like anything in medicine.
00:40.317 --> 00:45.884
[SPEAKER_01]: There's a dose, there's a regimen, because we're dealing with biology, the biology has this own rhythm.
00:46.044 --> 00:53.492
[SPEAKER_01]: I tell people just like, when you're sick with infection, you don't take your whole bottle of antibiotics, expecting that I'm cured, right?
00:53.753 --> 00:58.438
[SPEAKER_01]: You take it every four to six hours because you're respecting the rhythm of biology.
00:58.418 --> 01:01.183
[SPEAKER_01]: Welcome to the Dr. Joy Kong podcast.
01:01.203 --> 01:08.194
[SPEAKER_01]: This is where I have a chance to share with you some of the latest developments in the space of holistic health, longevity, and wellness.
01:08.615 --> 01:15.447
[SPEAKER_01]: I've always honored intellectual curiosity and scientific rigor, combined with real world practicality.
01:15.767 --> 01:20.175
[SPEAKER_01]: My goal is that what you learn here will help you live longer and live better.
01:20.475 --> 01:22.198
[SPEAKER_01]: Hope you enjoy the journey with me.
01:23.005 --> 01:41.507
[SPEAKER_00]: All right, so Joy Kong, MD, is a UCLA train triple board certified, triple board, wow, certified physician, American board of psychiatry and neurology, American board of addiction, medicine, and American board anti-aging and regenerative medicine.
01:42.348 --> 01:46.212
[SPEAKER_00]: I'm pretty sure you don't want to take any more tests at this point.
01:46.192 --> 02:01.323
[SPEAKER_00]: but she's the president of the Thia Center for regenerative medicine in Los Angeles, where she specializes in stem cell treatments to improve the functions of diverse organ systems in the body as well as for preventive and endless wellness purposes.
02:01.343 --> 02:05.972
[SPEAKER_00]: And I will say that, you know, I like to consult with her periodically, because I don't.
02:05.952 --> 02:09.557
[SPEAKER_00]: You know, I have a like a super duper grass once themselves.
02:10.077 --> 02:28.821
[SPEAKER_00]: She does some very interesting unique things with her stem cells She's also the medical director for avalanche surgery center She oversees all regenerative medicine treatments and she founded the American Academy of Integrated cell therapy where she provides training
02:28.801 --> 02:34.915
[SPEAKER_00]: I probably need to go to that course clinical evidence and aspects of clinical practice of stem cell treatments.
02:34.935 --> 02:46.101
[SPEAKER_00]: She has developed unique stem cell treatment protocols, including patent pending intranasal and needle-free male and female sexual wellness protocols.
02:46.081 --> 02:56.046
[SPEAKER_00]: She's the founder and CEO of Chiara Biologics, a company dedicated to providing cutting edge regenerative medicine products in the U.S. and the rest of the globe.
02:56.948 --> 03:02.723
[SPEAKER_00]: She's also a board member of the American Association of STEM Self-Ausitions and is a proponent.
03:02.703 --> 03:12.137
[SPEAKER_00]: of conducting high-quality clinical research and is a medical consultant for stem cell research projects to be conducting projects.
03:12.298 --> 03:17.385
[SPEAKER_00]: Okay, Dr. Kong is a firm believer in the therapeutic potentials of self-therapies.
03:17.405 --> 03:26.239
[SPEAKER_00]: She's lectured nationally and internationally on stem cell treatments and has exchanged ideas with a top stem cell scientists from around the globe.
03:26.719 --> 03:29.824
[SPEAKER_00]: So Dr. Kong, please give
03:38.292 --> 03:41.678
[SPEAKER_01]: Thank you so much, Dr. Frank, for such a wonderful introduction.
03:41.798 --> 03:43.220
[SPEAKER_01]: I'm so privileged to be here.
03:43.240 --> 03:58.365
[SPEAKER_01]: I have a really particular fondness for this crowd, because you guys are probably some of the most adventures and courageous people, because you believe in ozone therapy, you believe in the modality.
03:58.866 --> 03:59.727
[SPEAKER_01]: That's
03:59.707 --> 04:06.820
[SPEAKER_01]: effective and it's safe and you're willing to use it despite certain oppositions.
04:07.041 --> 04:10.327
[SPEAKER_01]: So I really love this group of doctors.
04:11.208 --> 04:17.300
[SPEAKER_01]: So today I'm going to be talking about regenerative medicine in autoimmune diseases and long COVID.
04:18.341 --> 04:19.183
[SPEAKER_01]: So
04:19.163 --> 04:23.068
[SPEAKER_01]: Use of stem cell therapy is very broad.
04:23.308 --> 04:26.752
[SPEAKER_01]: You know, it's broad range of possibilities.
04:26.993 --> 04:31.298
[SPEAKER_01]: So autoimmune diseases, one of the places where stem cell therapy really shines.
04:31.879 --> 04:42.572
[SPEAKER_01]: So I'm going to go over a few disease categories then end with lung COVID, which really is kind of a branch of this autoimmune dysregulation.
04:42.552 --> 04:53.424
[SPEAKER_01]: The traditional route of using stem cell therapy for autoimmune disease is using hematopuatic stem cell therapy, which are usually from bone marrow.
04:53.464 --> 04:58.110
[SPEAKER_01]: So that's the first stem cell therapy is using the bone marrow.
04:58.130 --> 04:58.310
[SPEAKER_01]: Right?
04:58.330 --> 05:02.675
[SPEAKER_01]: Bone marrow transplant people, you know, in the 60s, they didn't know they were doing stem cell therapy.
05:02.695 --> 05:04.837
[SPEAKER_01]: They were just transplanting bone marrow.
05:04.857 --> 05:08.001
[SPEAKER_01]: But then later on, we realized that that's actually stem cell therapy.
05:08.461 --> 05:09.943
[SPEAKER_01]: So using
05:09.923 --> 05:15.910
[SPEAKER_01]: a donor's bone marrow, that's one of the first ways of doing stem cell therapy.
05:17.492 --> 05:25.681
[SPEAKER_01]: But that kind of treatment, so the hematopuatic stem cells, those are the major, one of the major stem cell types in the bone marrow.
05:26.101 --> 05:34.851
[SPEAKER_01]: But that has a lot of potentials for rejection, so you need immune, suppressive medications, and that can really take a toll on patients.
05:34.831 --> 05:44.263
[SPEAKER_01]: Or you can use your own, but that is linked to a lot of morbidity and mortality, including infections and recurrence is pretty common.
05:44.784 --> 05:51.492
[SPEAKER_01]: So MIC is kind of as the newer cell type on the block and they realize, oh, oh my goodness.
05:51.512 --> 05:56.279
[SPEAKER_01]: So there's this particular cell type that's derived from the mesenchymal lineage.
05:57.921 --> 06:02.847
[SPEAKER_01]: But they have very little surface markers and mark the mesophoren.
06:02.827 --> 06:15.425
[SPEAKER_01]: and they have this immigulating properties so you can give it to people sometimes completely unmatched and people are doing great, you know, having all kinds of therapeutic responses.
06:15.946 --> 06:26.781
[SPEAKER_01]: So, yeah, so even with mismatch, HLA mismatch, they can hold me into the damage tissue and exert clinical benefit and the benefit tends to be much more sustained.
06:26.962 --> 06:28.564
[SPEAKER_01]: This is the Pylice study.
06:28.544 --> 06:34.761
[SPEAKER_01]: on allergenic MSEs for refractory lupus, SLE.
06:34.781 --> 06:40.677
[SPEAKER_01]: So what's interesting is that all immune diseases have been proposed as stem cell disorders.
06:41.579 --> 06:44.848
[SPEAKER_01]: And there are functional abnormalities
06:44.828 --> 06:59.852
[SPEAKER_01]: in the bone marrow MSCs, in patients with lupus, including defectiveness, in cytokine secretion, with the downregulation of different cytokines and RNA expressions.
07:00.573 --> 07:05.862
[SPEAKER_01]: And here's a study actually looking at 16 patients.
07:05.882 --> 07:08.406
[SPEAKER_01]: And they saw,
07:08.386 --> 07:18.499
[SPEAKER_01]: by using a local core derived MSEs that I one month after the treatment, these people has significant decrease in disease severity.
07:19.120 --> 07:24.788
[SPEAKER_01]: And they also showed that these loopous patients had improved levels of disease markers.
07:25.829 --> 07:31.677
[SPEAKER_01]: They improved their renal function, and clinically there seemed to be a shift
07:31.657 --> 07:47.880
[SPEAKER_01]: more of a balance between the TH-1 and TH-2 sites of the immune system and increase in T-Rex cells and the significant reduction in disease activity was achieved in all these 16 patients with no recurrence in three years.
07:48.140 --> 07:49.883
[SPEAKER_01]: So this is a very successful study.
07:50.143 --> 07:57.674
[SPEAKER_01]: So this one is another study looking at 40 patients and they use expanded on local core derived MICs.
07:58.395 --> 08:01.579
[SPEAKER_01]: They were giving these patients
08:01.559 --> 08:28.292
[SPEAKER_01]: on day zero and seven, and there were no averse reactions, so major clinical response was achieved in about a third of the patients, and there are also 40 percent of patients who had no clinical response, and at nine months the relapse rate was 12.5, at 12 months, 6.7, so they think that likely these people would require re-infusion in six months, so some kind of booster shot, so
08:28.272 --> 08:30.475
[SPEAKER_01]: you know, we do see this clinically.
08:31.577 --> 08:33.620
[SPEAKER_01]: There are people who are doing amazingly well.
08:34.622 --> 08:41.893
[SPEAKER_01]: I've seen people who have complete remission to the point where all their markers are normal.
08:41.933 --> 08:47.461
[SPEAKER_01]: So basically they are disease-free, but there are also people who need more infusion.
08:47.501 --> 08:51.327
[SPEAKER_01]: I think, you know,
08:51.307 --> 08:55.514
[SPEAKER_01]: kind of functional medicine crowd, that we know the health is very complex.
08:55.735 --> 09:00.884
[SPEAKER_01]: Our body is, you know, have so many things that's happening all like once.
09:00.924 --> 09:03.789
[SPEAKER_01]: We're dealing with a web, the web of biology.
09:04.230 --> 09:08.978
[SPEAKER_01]: So the stem cells can go in and provide some fundamental shifts.
09:08.958 --> 09:11.763
[SPEAKER_01]: in patients, but it's not covering all ground.
09:12.064 --> 09:28.215
[SPEAKER_01]: I think it would be naive to think just because stem cell therapy is amazing that I can just give you one treatment and then expect everybody to do an amazing new well because a person could be deficient in amino acids, could be deficient in minerals, could be, you know, hormonally,
09:28.195 --> 09:46.542
[SPEAKER_01]: depleted or have toxicity, so I always try to give people a realistic expectation that I'm not expecting miracles, I'm hoping for miracles, but I'm not expecting miracles, and then there may be a regiment that's needed, we may be looking at three treatments within, you know.
09:46.522 --> 09:59.494
[SPEAKER_01]: four to six months, so I want people to be prepared mentally and not expect this to be a miracle because like anything in medicine, it does.
09:59.754 --> 10:04.125
[SPEAKER_01]: There's a regimen because we're dealing with biology, biology has its own
10:04.105 --> 10:04.947
[SPEAKER_01]: this own rhythm.
10:05.207 --> 10:13.242
[SPEAKER_01]: You know, I tell people just like when you're sick with infection, you don't take your whole bottle of antibiotics, expecting that I'm cured, right?
10:13.503 --> 10:17.972
[SPEAKER_01]: You take it every four to six hours because you're respecting the rhythm of biology.
10:18.232 --> 10:20.376
[SPEAKER_01]: There's a way of helping the body repair.
10:20.797 --> 10:22.941
[SPEAKER_01]: Here's another example.
10:22.921 --> 10:27.548
[SPEAKER_01]: just looking at a secondary pathology from patients with lupus.
10:28.029 --> 10:30.132
[SPEAKER_01]: So, this is secondary osteoporosis.
10:30.953 --> 10:39.025
[SPEAKER_01]: So, what's interesting is that one of the mechanisms of the MSC's benefits could be through IL-17 suppression.
10:39.085 --> 10:45.174
[SPEAKER_01]: And that IL-17 is an inflammatory cytokine that's implicated in autoimmune diseases.
10:45.655 --> 10:51.544
[SPEAKER_01]: So, and these can be defective in the recipient's bone marrow.
10:51.524 --> 11:03.631
[SPEAKER_01]: So what happens is that the transplantation of MICs can promote healthy bone metabolism by establishing a new balance between the osteoplasts and osteoclasts.
11:04.653 --> 11:10.326
[SPEAKER_01]: And so here's another study using
11:10.525 --> 11:12.226
[SPEAKER_01]: and local cord MICs.
11:12.727 --> 11:20.073
[SPEAKER_01]: So they do have profound inhibitory effect on these particular cells, fibril blasts like synovial sites.
11:20.774 --> 11:30.042
[SPEAKER_01]: And inhibitory effect on these cells and then on the overactivation of T cells can really help these rheumatoid arthritis patients.
11:30.062 --> 11:32.204
[SPEAKER_01]: So we're moving onto rheumatoid arthritis.
11:32.764 --> 11:39.570
[SPEAKER_01]: One of the ways they induce such effect is by inducing T-rexal activation.
11:39.550 --> 11:43.518
[SPEAKER_01]: and T-Rex play a very important role in South Immune tolerance.
11:43.979 --> 11:56.243
[SPEAKER_01]: So, on Blocal Court, M.I.C.s can again shift the TH-1 TH-2 balance, and the infusion, systemic infusion, was able to reduce disease severity in mouse.
11:56.223 --> 12:08.396
[SPEAKER_01]: It's just a sight note, you know, people say, okay, so, you know, I give one person's themselves to another person is not a perfect match or the South's gonna stay, so that's a question that's been asked many times.
12:08.436 --> 12:10.679
[SPEAKER_01]: I've asked many experts from the field.
12:11.079 --> 12:19.548
[SPEAKER_01]: Some say, no, it's impossible for one person's self to say another, which is not true because bone marrow transplant, you know, is very successful.
12:19.648 --> 12:25.875
[SPEAKER_01]: And some say, yeah, it's very small
12:25.855 --> 12:27.638
[SPEAKER_01]: can stay in an animal's body.
12:27.678 --> 12:29.441
[SPEAKER_01]: So these are different species.
12:29.941 --> 12:34.589
[SPEAKER_01]: So even with that much difference in a Charlie marker, cells can stay.
12:34.609 --> 12:37.614
[SPEAKER_01]: So I think there's a really good chance that cells can stay.
12:37.634 --> 12:44.084
[SPEAKER_01]: And when you use younger cells, the cells have a better tendency to adapt to the host environment.
12:44.564 --> 12:50.614
[SPEAKER_01]: So if you are transplanting bone marrow stem cells, even if it's perfectly matched,
12:50.594 --> 12:51.876
[SPEAKER_01]: Perfect H. Ali matching.
12:52.176 --> 12:53.538
[SPEAKER_01]: There's still a chance rejection.
12:53.978 --> 13:00.787
[SPEAKER_01]: But if you're using young and local core blood stem cell, and local core blood composition is very similar to bone marrow composition.
13:01.187 --> 13:05.973
[SPEAKER_01]: So in those cases, there's very little rejection, even when it's completely unmatched.
13:06.294 --> 13:11.100
[SPEAKER_01]: So that's how different young cells are and versus older cells.
13:11.561 --> 13:14.584
[SPEAKER_01]: And when cells are younger, they get into the whole spotty.
13:14.885 --> 13:18.289
[SPEAKER_01]: There's much better chance that they will adapt.
13:18.269 --> 13:27.173
[SPEAKER_01]: So when you're older, it's almost like, you know, they've got their own thing, they have their own, you know, ideas that their own, you know, ways of doing things, some things are set.
13:27.454 --> 13:29.760
[SPEAKER_01]: But when they're younger, they're more malleable.
13:30.061 --> 13:33.510
[SPEAKER_01]: They're more able to adapt the host environment.
13:33.828 --> 13:37.594
[SPEAKER_01]: So in this study, they saw a good response in animal model.
13:37.995 --> 13:45.667
[SPEAKER_01]: And here's a fairly large study for humans, 170 two patients with active room to their arthritis.
13:46.489 --> 13:54.161
[SPEAKER_01]: And they had two groups, so they used the disease modifying anti-rumatic drugs in both groups.
13:54.982 --> 13:59.650
[SPEAKER_01]: One, they added placebo, the other one, they added a local court MSCs.
13:59.630 --> 14:06.484
[SPEAKER_01]: So only 40 million cells per infusion and they were able to see that after two weeks.
14:07.240 --> 14:13.267
[SPEAKER_01]: post-inthusion, there's significant remission in the group that used MSEs.
14:14.188 --> 14:17.913
[SPEAKER_01]: And the improvement was not seen in the group that had placebo.
14:18.634 --> 14:24.220
[SPEAKER_01]: And joint pain and swelling were alleviated within 12 hours and maintained throughout the study.
14:24.641 --> 14:25.862
[SPEAKER_01]: And that's pretty common.
14:26.002 --> 14:27.264
[SPEAKER_01]: I had one patient.
14:27.704 --> 14:33.231
[SPEAKER_01]: She was a cervical nurse and she was
14:33.211 --> 14:37.216
[SPEAKER_01]: begin to have rheumatoid arthritis symptoms, and she was not able to work.
14:38.258 --> 14:44.085
[SPEAKER_01]: So during the infusion, this is within, you know, 30 minutes of starting the infusion.
14:44.265 --> 14:49.051
[SPEAKER_01]: In the middle of the infusion, and she did this, she closed her fist, and she started crying.
14:49.652 --> 14:53.397
[SPEAKER_01]: And she said, I have not been able to close my fist for two months.
14:53.377 --> 15:01.510
[SPEAKER_01]: So it can happen that fast, and I hear that quite a bit, you know, swelling within a couple hours, the swelling the hands go down.
15:01.610 --> 15:04.494
[SPEAKER_01]: So the end-time flammatory effect can happen very fast.
15:04.795 --> 15:08.841
[SPEAKER_01]: So I tell people that there are different stages of healing with stem cell therapy.
15:09.262 --> 15:11.385
[SPEAKER_01]: So when people say, when can I expect benefit?
15:11.365 --> 15:16.274
[SPEAKER_01]: Well, let's look at what the cells are doing and what are the stages.
15:16.554 --> 15:19.940
[SPEAKER_01]: The first stage is the anti-inflammatory stage, so that can happen very fast.
15:20.281 --> 15:26.472
[SPEAKER_01]: To the point where I treated Alzheimer's patient, she was so stuck.
15:26.452 --> 15:31.059
[SPEAKER_01]: in her, I think it's the neuro-inflammation that she had not been able to feed herself for a month.
15:31.479 --> 15:32.401
[SPEAKER_01]: She was not eating.
15:32.421 --> 15:33.703
[SPEAKER_01]: The food would be in front of her.
15:34.103 --> 15:35.285
[SPEAKER_01]: She would not her brain.
15:35.345 --> 15:36.887
[SPEAKER_01]: And there was no signal coming through.
15:36.927 --> 15:39.871
[SPEAKER_01]: She could not pick up a knife and fork, even though she's hungry.
15:39.952 --> 15:40.392
[SPEAKER_01]: She couldn't.
15:40.913 --> 15:44.238
[SPEAKER_01]: But the next day after the Samsung treatment, the food was in front of her.
15:44.278 --> 15:46.341
[SPEAKER_01]: She picked up knife and fork, and she's to set her up.
15:46.401 --> 15:48.844
[SPEAKER_01]: And her husband was looking at her, you know, in shock.
15:48.864 --> 15:51.328
[SPEAKER_01]: And she looked up at him, it's like, what's your problem?
15:51.308 --> 16:09.942
[SPEAKER_01]: So, yeah, so it can happen that fast and that's an anti-inflammatory effect, but the second stage is the tissue rebuilding and that takes time, so whatever you're trying to do, you know, if it's musculoskeletal issue or systemic autoimmune issue or, you know, any organ repair,
16:09.922 --> 16:30.630
[SPEAKER_01]: there is a stage of slowly the cells is going to tell the local tissue to start to divide or the cells could differentiate locally and that takes time and that takes weeks to months time and the last stage is the genetic modification because the cells do send out microRNAs which could
16:30.610 --> 16:36.464
[SPEAKER_01]: go into the cell nucleus and make genetic changes and produce long lasting benefits.
16:36.484 --> 16:48.754
[SPEAKER_01]: And these cells also can conduct mitochondria transfer, so it can give the recipient cells fresh new mitochondria, so elevating the cellular energy, and that could have much longer benefit.
16:48.734 --> 16:52.479
[SPEAKER_01]: Another condition psoriasis that I've seen good results clinically.
16:52.919 --> 17:02.031
[SPEAKER_01]: This is animal study, the TH17 cells, and their related cytokines are pretty important in the pathogenesis of psoriasis.
17:02.771 --> 17:09.480
[SPEAKER_01]: And MSC's can inhibit the TH17 cells and induce the T-rex cells.
17:10.181 --> 17:18.471
[SPEAKER_01]: And they've shown some defect in the patient's cellular composition.
17:18.451 --> 17:27.109
[SPEAKER_01]: they could, you know, the MSC's from their skin, their ability to inhibit the T-cell proliferation is much decreased.
17:27.630 --> 17:36.088
[SPEAKER_01]: So that's another reason, you know, sometimes when you try to use a person's own stem cells, you know, genetically they're just not as...
17:36.068 --> 17:36.969
[SPEAKER_01]: as effective.
17:37.129 --> 17:41.795
[SPEAKER_01]: You know, there's something that's different in the disease patients cells.
17:42.235 --> 17:46.580
[SPEAKER_01]: It's another reason that I'm a proponent at using healthy donor sources.
17:46.720 --> 17:47.841
[SPEAKER_01]: There are many other reasons.
17:47.902 --> 17:52.867
[SPEAKER_01]: I have a lecture, I've given in a few conferences about different cell sources.
17:53.528 --> 17:57.472
[SPEAKER_01]: It's not just that these cells are young and healthy.
17:58.213 --> 17:59.214
[SPEAKER_01]: They're more potent.
17:59.635 --> 18:05.822
[SPEAKER_01]: They seek to create more anti-inflammatory
18:05.802 --> 18:07.364
[SPEAKER_01]: They're also our safer.
18:07.424 --> 18:09.326
[SPEAKER_01]: So I'll talk a little bit about that later.
18:09.707 --> 18:12.310
[SPEAKER_01]: So this is study on severe psoriasis.
18:12.750 --> 18:27.287
[SPEAKER_01]: So the background was that, you know, so back in 2002, four patients under went autologues, hematopoedic stem cell treatments, so using cells from their own bone marrow re-infused and they all relapsed within 21 months.
18:27.267 --> 18:38.042
[SPEAKER_01]: And then, so in the literature, between 1990 and 2002, nine patients had allergenic, the hematopoietics stem cell transplant.
18:38.062 --> 18:45.612
[SPEAKER_01]: The longest time for remission was four years and there's one patient actually remained.
18:46.093 --> 18:52.482
[SPEAKER_01]: So there's a surratic rash, the rash remained absent for 17 years after two treatments.
18:52.462 --> 19:01.617
[SPEAKER_01]: And this case study was a 29-year-old guy with extensive psoriasis in age 13 and also polyarthritis.
19:02.077 --> 19:11.753
[SPEAKER_01]: So he later on found out he also had golden-duced a plastic anemia and he received
19:11.733 --> 19:18.779
[SPEAKER_01]: you know, and that point, you know, for the NEMIA, not, you know, I'm sure that they weren't doing it thinking that they were trying to treat psoriasis.
19:19.420 --> 19:41.740
[SPEAKER_01]: So, he received alugienic, he metapuetic stem cells from a, you know, compatible female sibling, and they, there was some acute graft versus halts reaction, so they had to use medications, you know, including steroid for seven months,
19:41.720 --> 19:46.245
[SPEAKER_01]: And so I'm going to move on to inflammatory bowel disease.
19:47.693 --> 19:54.799
[SPEAKER_01]: So stensile transplant has definitely been used for inflammatory bowel diseases.
19:55.360 --> 20:01.886
[SPEAKER_01]: And again, you know, the, where I started was the metabolic stem cells and they used autologous stem cells.
20:02.526 --> 20:17.700
[SPEAKER_01]: The first study, 900 patients, so that they did a cohort study, the survival rate of using a person's own the metabolic stem cells was 85% at five years.
20:17.680 --> 20:24.752
[SPEAKER_01]: And 30% had complete response, but the problem is, again, these people are on chemotherapy regimen.
20:25.052 --> 20:31.162
[SPEAKER_01]: They had to take antibiotics and steroid, so that's really not an ideal kind of treatment.
20:31.824 --> 20:40.498
[SPEAKER_01]: And they could also use allergenic hematopoietics stem cells, which usually means bone marrow transplant.
20:40.478 --> 20:42.942
[SPEAKER_01]: unless they were using um, local core blood cells.
20:43.042 --> 20:45.685
[SPEAKER_01]: But I think these are our bone marrow transplant patients.
20:46.146 --> 20:55.820
[SPEAKER_01]: So the allergenic hematopoedic stem cell transplant can potentially correct the underlying disease genetically, right, using a healthy donor cells.
20:56.261 --> 21:02.149
[SPEAKER_01]: But that also is associated with complication and mortality rate, because
21:02.129 --> 21:07.257
[SPEAKER_01]: He might have poetic stem cell still, there's a chance and tendency for mismatch.
21:07.978 --> 21:13.046
[SPEAKER_01]: And people have to use, again, use certain medications to help prevent that.
21:14.148 --> 21:21.359
[SPEAKER_01]: This study, even using on vocal core blood, there's still some chance, because on vocal core blood have almost no MSCs in it.
21:21.399 --> 21:23.362
[SPEAKER_01]: And well, it has a very tiny fraction.
21:23.723 --> 21:25.926
[SPEAKER_01]: So bone marrow has about 0.1,
21:25.906 --> 21:32.958
[SPEAKER_01]: A point zero one to point one percent MSEs in the in the bone marrow self and very similar in the and local core blood.
21:32.998 --> 21:41.433
[SPEAKER_01]: So you have very few MSEs which modulated immune system prevent graft versus host disease and really help to calm the system.
21:41.473 --> 21:49.888
[SPEAKER_01]: So when you have very little MSEs in in the core blood or bone marrow, you have much higher chance of having these reactions.
21:49.868 --> 22:02.785
[SPEAKER_01]: And this is why Joanne Kersberg, who is in Duke University, she's doing autism study using a local core blood, is much easier and I think safer and more effective than bone marrow transplant.
22:02.805 --> 22:15.943
[SPEAKER_01]: But she still has to pre-medicate all these kids with these medications and steroid, which I'm still not a fan of when there's ready source of mesenchymal stem cells that can really prevent these kind of rejections.
22:15.923 --> 22:18.708
[SPEAKER_01]: Then we come to mesenchymostensile transplantation.
22:18.728 --> 22:24.678
[SPEAKER_01]: So these are the newer treatments, because all we knew were bone marrow before, but now we know much better.
22:25.620 --> 22:28.645
[SPEAKER_01]: So you can do local injection of these mesenchymostensiles.
22:29.086 --> 22:36.819
[SPEAKER_01]: So this study, they looked at Paranofistrolus, and they were using 30 million MSCs.
22:37.681 --> 22:40.125
[SPEAKER_01]: And that was more...
22:40.105 --> 22:43.269
[SPEAKER_01]: If efficacious, then 10 million versus 90 million.
22:43.309 --> 22:44.290
[SPEAKER_01]: So it's very interesting.
22:44.330 --> 22:50.757
[SPEAKER_01]: I've seen that quite a bit that there's a dose response, and it doesn't mean more is better.
22:50.917 --> 22:55.383
[SPEAKER_01]: Sometimes you have a dose range that's much more ideal.
22:55.783 --> 22:59.127
[SPEAKER_01]: And if you go outside and range, maybe it's going to be less efficacious.
22:59.567 --> 23:00.849
[SPEAKER_01]: So pretty good.
23:00.889 --> 23:07.176
[SPEAKER_01]: The local injection of these stem cells, 85.7% success rate at week 12.
23:07.156 --> 23:09.900
[SPEAKER_01]: and the placebo only 33 percent.
23:10.381 --> 23:13.045
[SPEAKER_01]: And then you can also infuse these cells systemically.
23:13.505 --> 23:25.603
[SPEAKER_01]: So the first human trial was nine patients with active Crohn's and they received a IV bone marrow MSEs and three out of the 10 patients achieved clinical response by day 14.
23:25.583 --> 23:45.364
[SPEAKER_01]: You can also do IV, so there's an IV study IV bone marrow MSCs for moderate to severe Crohn's polymer study, 148 out of 207 patients reached remission in 28 days, which is pretty good, 148 out of 207.
23:45.344 --> 23:54.822
[SPEAKER_01]: But it's still not 207 and so clinically, you know, that's why I give I tell patients to, you know, temper your enthusiasm.
23:54.882 --> 23:58.970
[SPEAKER_01]: We're hopeful, but we're, is not guaranteed.
23:58.990 --> 24:00.253
[SPEAKER_01]: I mean, nothing's guaranteed in the medicine.
24:00.313 --> 24:05.142
[SPEAKER_01]: I will love to guarantee patients of complete healing, you know, that, you know, that 60, some,
24:05.122 --> 24:18.806
[SPEAKER_01]: patient and out of 207 to me is still a lot and it's you know it's very uncomfortable for me as as a clinician but but the fact is that I'm offering hope so much hope for those 148 patients.
24:19.207 --> 24:26.259
[SPEAKER_01]: Here's another study on Crohn's 82 patients diagnosed with Crohn's disease and they're on steroid maintenance.
24:26.439 --> 24:29.745
[SPEAKER_01]: They were given IV infusion.
24:29.725 --> 24:38.764
[SPEAKER_01]: So 41 of those were selected to receive infusion and you would see this dose range, you know, 1 million per kilo that's pretty standard.
24:39.225 --> 24:43.894
[SPEAKER_01]: But just remember that this dose range is established using expanded cells.
24:44.556 --> 24:48.544
[SPEAKER_01]: There's a lot of difference between unexpected and expanded cells.
24:48.524 --> 24:50.266
[SPEAKER_01]: There's a bit of a controversy.
24:50.306 --> 24:58.377
[SPEAKER_01]: There's people overseas who are doing a lot of these selling expansions and people seem to believe that more is better.
24:58.958 --> 25:05.227
[SPEAKER_01]: And even when the cells are not expanded, the same type of cells, more doesn't mean it's better.
25:05.607 --> 25:11.275
[SPEAKER_01]: The point you start to expand the cells, you're changing the characteristics of the cells.
25:11.255 --> 25:22.852
[SPEAKER_01]: unavoidable, especially after about three or four passages, but just remember when you expand the cells, you're putting them in the petri dish, you know, some kind of container in the incubator.
25:22.893 --> 25:32.487
[SPEAKER_01]: The cells that's well adapted to this environment, to this particular artificial environment, are going to be the cell that divide.
25:32.467 --> 25:35.110
[SPEAKER_01]: So, and they tend to gain more characteristics.
25:35.130 --> 25:43.480
[SPEAKER_01]: So, as they divide, they would express surface markers that show them their characteristics as whoever the donor is.
25:43.881 --> 25:49.968
[SPEAKER_01]: So, you will get these further differentiated cells that would express more surface markers.
25:50.308 --> 25:54.373
[SPEAKER_01]: They tend to bring about more rejection, type of reaction.
25:54.774 --> 25:59.379
[SPEAKER_01]: But also, they're losing capabilities and characteristics of the younger stem cells.
25:59.860 --> 26:02.423
[SPEAKER_01]: And many of them are no longer stem cells.
26:02.403 --> 26:10.619
[SPEAKER_01]: remember the dose calculation, and just because in a study says one million per kilo just remember these are expanded cells.
26:10.679 --> 26:14.085
[SPEAKER_01]: Native cells that have never been expanded will act differently.
26:14.506 --> 26:17.492
[SPEAKER_01]: So these people received infusions.
26:17.472 --> 26:20.059
[SPEAKER_01]: One week apart, four infusions total.
26:20.079 --> 26:24.911
[SPEAKER_01]: At 12 months, they show the disease scores decrease.
26:25.132 --> 26:28.520
[SPEAKER_01]: So the first one, it was the score decreased by 62.5%.
26:29.804 --> 26:33.473
[SPEAKER_01]: Compared to the placebo, that's 23.6%.
26:33.453 --> 26:40.783
[SPEAKER_01]: And another disease score is decreased by 3.4% compared to 1.2 in the control group.
26:41.464 --> 26:44.067
[SPEAKER_01]: And their steroid doses were decreased.
26:45.128 --> 26:50.676
[SPEAKER_01]: The placebo group only decreased the dose by 1.2 milligrams per day.
26:51.076 --> 26:54.060
[SPEAKER_01]: But this treated groups
26:54.040 --> 26:59.508
[SPEAKER_01]: were able to have the dose decrease by 4.2 milligrams.
26:59.528 --> 27:03.314
[SPEAKER_01]: So significant reduction in the amount of steroid that they have to use.
27:04.375 --> 27:08.601
[SPEAKER_01]: And here's just a visual of the changes at 12 months in their mucosa.
27:09.302 --> 27:13.969
[SPEAKER_01]: And then I've mentioned a couple of disease briefly, so sclerodoma.
27:14.310 --> 27:16.032
[SPEAKER_01]: So you know, the...
27:16.282 --> 27:24.274
[SPEAKER_01]: You know, because the certain diseases are more rare, the cases are, you know, a lot less so it's harder to find studies.
27:25.476 --> 27:30.865
[SPEAKER_01]: So we're still so new in the stem cell field, you know, as time goes on, there's gonna be more and more studies.
27:30.965 --> 27:34.410
[SPEAKER_01]: But this is the girl Derma, which is the top disease.
27:34.831 --> 27:38.356
[SPEAKER_01]: So they are using a local cord MSEs.
27:39.158 --> 27:41.361
[SPEAKER_01]: So they obtain these using collagenase.
27:41.341 --> 27:43.603
[SPEAKER_01]: and sales expansion.
27:43.663 --> 27:47.967
[SPEAKER_01]: So in the case, in FDA's eyes, then you are creating a drug.
27:48.427 --> 27:53.092
[SPEAKER_01]: So a lot of them sell, and book course them sell products using the country.
27:53.612 --> 27:58.997
[SPEAKER_01]: The lots are not supposed to use collagenese to free the cells from the matrix, and they're not supposed to expand them, right?
27:59.017 --> 28:11.348
[SPEAKER_01]: If you do any of these two things, then you're creating a drug in the FDA's eyes, and then you need to conduct an investigation in the new drug, IND study, which is why so many of these companies go overseas
28:11.328 --> 28:19.147
[SPEAKER_01]: The study is costly both in time and in money so they don't want to do that in this study That's what they did.
28:19.448 --> 28:28.830
[SPEAKER_01]: They freed the cells using collagenese and expanded them and then they used two million per kilo Treatment so two patients the first
28:28.810 --> 28:38.348
[SPEAKER_01]: Um, the first time when I did treated these patients, they give them four plasma furuses followed by, uh, retooks a mob, and then they give them IV stem cells.
28:38.368 --> 28:44.119
[SPEAKER_01]: So they were able to, uh, achieve, um, sustained remission.
28:44.099 --> 28:47.625
[SPEAKER_01]: for 12 months and 16 months, for these two patients.
28:47.946 --> 28:49.849
[SPEAKER_01]: And the second time they didn't even pre-treat them.
28:49.909 --> 28:51.272
[SPEAKER_01]: I think they were just being cautious.
28:51.312 --> 28:51.893
[SPEAKER_01]: They weren't sure.
28:52.294 --> 29:02.412
[SPEAKER_01]: And the second time they forgot about, you know, they took out the plasma ferrisis and the medication, and they both achieved improvement in their mobility and function.
29:02.392 --> 29:06.377
[SPEAKER_01]: And here's a case about sarcoidosis.
29:07.279 --> 29:14.488
[SPEAKER_01]: And so this is actually somebody that sarcoidosis for some time and tried all kinds of medications.
29:15.109 --> 29:20.957
[SPEAKER_01]: You can see the list of medications, the method of trexade, touch the cyclone, and with limited success.
29:20.937 --> 29:27.485
[SPEAKER_01]: and they were using systemic cortical steroids and they couldn't really reduce the dose.
29:27.505 --> 29:32.051
[SPEAKER_01]: So she was stabilized on the low dose steroid and methyltrexate.
29:32.071 --> 29:39.601
[SPEAKER_01]: So eight years after the diagnosis of sarcoidosis, she was diagnosed with AML, AML, leukemia.
29:40.162 --> 29:46.590
[SPEAKER_01]: And after chemotherapy, she was able to receive a local core blood
29:46.570 --> 29:48.413
[SPEAKER_01]: stem cell transplantation.
29:48.493 --> 29:56.887
[SPEAKER_01]: So five months after the transplant, she, um, to all the immune suppressive drugs were stopped and she did not have any recurrence.
29:56.907 --> 29:59.952
[SPEAKER_01]: And four years later, she still asymptomatic.
29:59.972 --> 30:08.867
[SPEAKER_01]: So that this kind of another incidental, they were treating something else and they have to give her this, um, the hematopoietics stem cell transplantation.
30:09.268 --> 30:11.852
[SPEAKER_01]: And then it cured her of sarcoidosis.
30:11.832 --> 30:23.366
[SPEAKER_01]: Now, we come to the subject of long COVID, so just kind of, you know, overview, research statistics still, there's not, you know, not that much.
30:23.426 --> 30:29.614
[SPEAKER_01]: We're still new in this, but I just want to give your overview, you know, about long COVID and then, you know, show you one case.
30:30.054 --> 30:39.426
[SPEAKER_01]: So long COVID has many names, you know, there's, I don't know why they come up with so many names, long-haul COVID, post-acute
30:39.406 --> 30:39.947
[SPEAKER_01]: P.A.
30:39.967 --> 30:42.110
[SPEAKER_01]: as C, long-term effect of COVID in any house.
30:42.130 --> 30:57.090
[SPEAKER_01]: So the long names, a definition, is that there are symptoms and conditions that continue after initial infection, and generally they don't diagnose people with long COVID until four weeks after the initial infection.
30:57.690 --> 31:06.342
[SPEAKER_01]: And the estimated incidence is about 10 to 30% of non-hospitalized cases, but 50 to 70% of a hospitalized cases.
31:06.592 --> 31:09.196
[SPEAKER_01]: and tend to 12% of vaccinated cases.
31:10.038 --> 31:24.060
[SPEAKER_01]: The prevalence as of January this year, 15% of all adults in the U.S. had reported some kind of long COVID symptom, and 6% had recurrent symptoms.
31:24.040 --> 31:37.583
[SPEAKER_01]: highest percentages in the age group of 36 to 50, and most are in the non-hospitalized patients, and they have, you know, because they had mild or acute illness, because that's the majority of the COVID-19 cases.
31:38.445 --> 31:45.677
[SPEAKER_01]: And there's even a disability, I guess, assigned to long COVID, back in July 2021.
31:45.657 --> 31:53.549
[SPEAKER_01]: So the symptoms are, you know, wide range over 200 symptoms have been identified, you know, involving many organ systems.
31:54.390 --> 32:08.712
[SPEAKER_01]: And so common, common new onset symptoms, including cardiovascular, thrombotic, cerebral vascular diseases, diabetes, type 2 diabetes, major, you know, chronic fatigue,
32:08.692 --> 32:27.966
[SPEAKER_01]: dysautonomia, including a pot syndrome, so they're general symptoms, fatigue, malaise fever, respiratory symptoms, of course, and heart symptoms, and there's neurological difficulties, digestive issues, and some other symptoms like joint pain, rash, and changing menstrual cycle.
32:27.946 --> 32:35.076
[SPEAKER_01]: And the proposed mechanism for long COVID is that there are many potential mechanisms.
32:35.396 --> 32:40.663
[SPEAKER_01]: So some think that there are reservoirs of these the virus in different tissues.
32:41.645 --> 32:47.693
[SPEAKER_01]: And other proposed mechanisms include immune dysregulation with or without.
32:47.673 --> 33:04.618
[SPEAKER_01]: reactivation of other pathogens in the body, like EVV or herpes virus, and also another proposed mechanism is that there's some kind of effect on the microbiome caused by the virus, or there's this
33:04.598 --> 33:20.678
[SPEAKER_01]: new autoimmunity that's triggered by the virus, or, you know, well, know about the clotting microvascular clotting with endothelial dysfunction, that's another mechanism, or even dysfunctional signaling in the brain stem, or vagus nerve.
33:20.858 --> 33:22.860
[SPEAKER_01]: So, MSCs for long COVID.
33:23.261 --> 33:29.388
[SPEAKER_01]: So, we've seen MSCs having therapeutic efficacy in patients with acute lung injury and ARDS.
33:30.309 --> 33:34.234
[SPEAKER_01]: What's interesting, I was very
33:34.214 --> 34:02.348
[SPEAKER_01]: In 2020, when everything was starting, already there were six studies in China using stem cells MSEs to treat patients with acute COVID and it was very encouraging, multiple studies they all showed that these people were on ventilators, they were, you know, in severe conditions within six days, these people were out of the hospital, so it was in a lot of elderly patients,
34:02.328 --> 34:09.896
[SPEAKER_01]: And then there are a lot of studies also have shown MSC benefits in improving lung function for post and lung COVID patients.
34:10.836 --> 34:14.540
[SPEAKER_01]: So these are the main mechanisms of MSC's function.
34:15.021 --> 34:19.785
[SPEAKER_01]: And a lot of times people ask me, you know, can't stand cells help me with this condition.
34:20.546 --> 34:23.349
[SPEAKER_01]: And, you know, some of the conditions are obscure.
34:23.769 --> 34:24.690
[SPEAKER_01]: So there's no studies.
34:25.111 --> 34:27.373
[SPEAKER_01]: Then I, you know,
34:27.353 --> 34:33.622
[SPEAKER_01]: So the patient down we talk about the pathophysiology, you know, what happened, what was its condition about?
34:33.662 --> 34:34.603
[SPEAKER_01]: How does it come about?
34:34.643 --> 34:37.307
[SPEAKER_01]: What was the underlying mechanism of your disease?
34:37.788 --> 34:44.196
[SPEAKER_01]: So then I see, and I look at how MSC's work, and then I'll see if we can dovetail.
34:44.657 --> 34:49.924
[SPEAKER_01]: If the way MSC works can actually target how the disease is coming about.
34:50.425 --> 34:56.854
[SPEAKER_01]: So anti-inflammatory action is a huge, one of the biggest ways that these MSC's
34:56.834 --> 34:58.926
[SPEAKER_01]: function and immune regulation.
34:58.987 --> 35:01.461
[SPEAKER_01]: So almost all
35:01.829 --> 35:06.395
[SPEAKER_01]: chronic illnesses will have inflammation and immune dysregulation as part of the picture.
35:07.296 --> 35:09.419
[SPEAKER_01]: You know, I don't care even if you had genetic diseases.
35:09.439 --> 35:12.743
[SPEAKER_01]: A lot of times the gene is not giving you the disease.
35:13.084 --> 35:16.288
[SPEAKER_01]: It's a downstream dysregulation and damage to your organs.
35:16.668 --> 35:18.170
[SPEAKER_01]: That's causing you the dysfunction.
35:18.271 --> 35:25.440
[SPEAKER_01]: So if we can look at the end organ, yes, we can, you know, there's a rescue function from these MSEs.
35:26.541 --> 35:27.803
[SPEAKER_01]: So that's the...
35:27.783 --> 35:29.626
[SPEAKER_01]: anti-apeptotic properties.
35:29.746 --> 35:44.129
[SPEAKER_01]: So on top of the immune regulation, immune modulation and anti-flemeter actions, there's also the anti-apoptotic function where the stem cells can rescue damage or semi-damage tissue and reverse the damage.
35:44.509 --> 35:46.973
[SPEAKER_01]: SEM cells can also
35:46.953 --> 35:50.359
[SPEAKER_01]: help break down scars, so anti-fibrodic properties are really important.
35:50.379 --> 35:55.889
[SPEAKER_01]: I've seen great results in my own patient with COPD and liver cirrhosis.
35:56.190 --> 36:00.658
[SPEAKER_01]: They can break down the scar tissue or even testicular nodules.
36:00.698 --> 36:02.381
[SPEAKER_01]: I've seen that disappear.
36:02.762 --> 36:06.649
[SPEAKER_01]: So the cells never fail to surprise me.
36:06.629 --> 36:26.914
[SPEAKER_01]: In the cells also have a pro-apoptotic properties in cases of senescent cells or pre-cancers or cancer's changes, so MSC's have been used for as a treatment for cancer because it does have the capability to send signals to tumors and to trigger program cell death.
36:27.134 --> 36:33.902
[SPEAKER_01]: So in the cases where they can detect cancer cells,
36:33.882 --> 36:54.321
[SPEAKER_01]: one interesting fact is that as we get older, even though we have our MSCs, our MSCs are having reduced capability of recognizing cancer, so that's why you hear this circulating fear that MSC treatments or stem cell treatment can promote cancer, and that's really
36:54.301 --> 37:02.973
[SPEAKER_01]: mostly happening when you use a person's own stem cells, because your own stem cells have lots some capabilities of recognizing cancer.
37:03.413 --> 37:24.021
[SPEAKER_01]: I call it cellular cinescence or cellular dementia, you know, it's lost certain abilities to tell that this cell doesn't belong here, whereas if you use young cells like from a local court, they are much better at detecting
37:24.001 --> 37:26.447
[SPEAKER_01]: when you age your MSC's age with you.
37:26.969 --> 37:29.836
[SPEAKER_01]: And the MSC's also have antimicrobial properties.
37:29.876 --> 37:32.944
[SPEAKER_01]: They can secret antimicrobial peptides directly.
37:32.984 --> 37:35.571
[SPEAKER_01]: They promote endogenesis.
37:35.972 --> 37:39.040
[SPEAKER_01]: So they help with vascular formation.
37:39.020 --> 37:43.287
[SPEAKER_01]: to supply the tissue with nutrients.
37:43.307 --> 37:55.208
[SPEAKER_01]: And they, of course, have this local, you know, what's called paracrin effect, conducting this local regenerative activities to tell local stem cells.
37:55.509 --> 37:57.552
[SPEAKER_01]: So so much of what MSC does,
37:57.532 --> 38:01.259
[SPEAKER_01]: is not to differentiate and become your own tissue cells.
38:01.640 --> 38:06.008
[SPEAKER_01]: It's actually to talk to your locals, you know, population that's the liver.
38:06.268 --> 38:07.751
[SPEAKER_01]: You know, I'm talking to the liver cells.
38:07.791 --> 38:09.354
[SPEAKER_01]: There are liver stem cells.
38:09.695 --> 38:15.506
[SPEAKER_01]: So MSC's is going to tell the liver stem cells is time for you to divide and replenish the tissue.
38:15.546 --> 38:17.109
[SPEAKER_01]: So that's what's happening a lot.
38:18.031 --> 38:19.894
[SPEAKER_01]: Even in musculoskeletal,
38:19.874 --> 38:25.927
[SPEAKER_01]: conditions, telling the cartilage stem cells to re-generate and start to rebuild the cartilage.
38:25.947 --> 38:30.416
[SPEAKER_01]: So that's really one of the things that I think a lot of people have the missed understanding.
38:30.436 --> 38:35.487
[SPEAKER_01]: They think these cells are just going in and start to become the cells of different tissues.
38:35.888 --> 38:38.052
[SPEAKER_01]: That has been...
38:38.032 --> 38:46.045
[SPEAKER_01]: kind of disproven, you know, in the scientific community over and over again, if you start reading articles, it just becomes, you know, it's the same, you know, it's just a repeated theme.
38:46.786 --> 38:56.361
[SPEAKER_01]: And then the mitochondria transfer, which I think is super cool, because you actually are getting fresh new mitochondria, and we all know how crucial mitochondria is for our,
38:56.341 --> 38:59.847
[SPEAKER_01]: for our cellular function and health of the body.
39:00.928 --> 39:03.693
[SPEAKER_01]: So, how do MSC's help in long COVID?
39:04.133 --> 39:18.116
[SPEAKER_01]: So, I talked about how MSC's work, so MSC's do exhibit immune-suppressive properties, so they can suppress the over-activation, the over-reaction of the immune system from the COVID-19.
39:18.156 --> 39:22.062
[SPEAKER_01]: And that's the one thing that's, you know, that's people fear as this,
39:22.042 --> 39:23.726
[SPEAKER_01]: drastic over reaction.
39:24.287 --> 39:35.414
[SPEAKER_01]: And MSEs can also locate to the inflamed lung tissue, and they can see create factors that modulate the immune system prevent the oxidative damages and fibrosis that belong.
39:35.735 --> 39:39.544
[SPEAKER_01]: So, you know, I want to dispel this myth about
39:39.524 --> 39:56.503
[SPEAKER_01]: stem cells when given IV that are trapped in the lungs, I think it's naive because later studies have shown that when you put, you know, mesenchymos stem cells into the IV route systemically.
39:56.483 --> 40:02.152
[SPEAKER_01]: Yes, initially, they're going to be in the lungs, but within three days, you can't detect them in the lungs because they're gone.
40:02.172 --> 40:14.692
[SPEAKER_01]: They're back into systemic circulation and to just look at the size of the cells and then looking at the size of the basculature in the lungs, I think it's really underestimating what these cells can do.
40:15.212 --> 40:24.567
[SPEAKER_01]: They can't squeeze through different places, so they don't just, you know, I'm this big, so I can't go anywhere.
40:24.547 --> 40:33.276
[SPEAKER_01]: travel in your capillaries, it goes to various tissues, and it travels out of your capillary and go into your neighboring tissues.
40:33.577 --> 40:35.999
[SPEAKER_01]: So they go in and out of the blood vessels.
40:36.280 --> 40:37.961
[SPEAKER_01]: So there's a lot more fluidity.
40:38.822 --> 40:46.490
[SPEAKER_01]: So I think it's time to dispel that myth that when we give some body, IV stem cells, and they're just going to all sit in the lungs.
40:46.731 --> 40:51.075
[SPEAKER_01]: If you have a lot of lung anthology and fibrosis and inflammation, yes, you bet.
40:51.095 --> 40:53.558
[SPEAKER_01]: They're going to sit there because they're really attracted to
40:53.538 --> 40:55.762
[SPEAKER_01]: to, you know, the presentation of the area.
40:56.143 --> 40:58.728
[SPEAKER_01]: But if you don't have any long problems, no, they're going to get out of there.
40:58.948 --> 41:02.735
[SPEAKER_01]: Messies also exert, at the immune modulation horizon we talked about.
41:02.836 --> 41:08.847
[SPEAKER_01]: So they exert this through the paracrin interactions, so local tissue, local signaling.
41:08.827 --> 41:10.650
[SPEAKER_01]: or even sell to cell contact.
41:10.930 --> 41:14.155
[SPEAKER_01]: The MSCs can't put it like this tentacles.
41:14.175 --> 41:19.984
[SPEAKER_01]: They can put their foot on another cell and start to talk with other cells directly.
41:20.906 --> 41:25.593
[SPEAKER_01]: They can do this exosome, extracellular vesicles.
41:25.893 --> 41:31.181
[SPEAKER_01]: So their exosomes are vesicles of certain size, only 50 to 200 microns.
41:31.422 --> 41:34.166
[SPEAKER_01]: But they're also other larger extracellular vesicles.
41:34.406 --> 41:36.449
[SPEAKER_01]: So there are a lot of these packets.
41:36.469 --> 41:37.551
[SPEAKER_01]: The cells can send out.
41:37.531 --> 41:45.367
[SPEAKER_01]: And they can also, you know, they can affect your immune system through, you know, affecting many cell types.
41:45.989 --> 41:53.464
[SPEAKER_01]: And they're capable of repairing and regenerating epithelial and endocelial tissues, and they'll be alive in the lungs.
41:53.444 --> 41:59.777
[SPEAKER_01]: MSCs can also attract functional cells to a niche in the wounded area of the lungs.
42:00.278 --> 42:04.427
[SPEAKER_01]: So that's the this I call them the conductor in the symphony regeneration.
42:04.467 --> 42:09.057
[SPEAKER_01]: They they're able to to call upon different cell types.
42:09.037 --> 42:15.889
[SPEAKER_01]: And they can replenish stem cell pool by endowing stemness.
42:15.989 --> 42:22.320
[SPEAKER_01]: This is really exciting, really fun, that they can endow differentiated cells with stemness.
42:22.701 --> 42:30.555
[SPEAKER_01]: So getting them to go back in their lineage and become more flexible and more primitive.
42:30.535 --> 42:49.270
[SPEAKER_01]: So they can transfer their own stem cell characteristics to, for example, they showed in, they can transfer that characteristic to differentiated alveoli epithelial cells in the long, long environment when it's damaged.
42:49.250 --> 42:57.238
[SPEAKER_01]: And, but MSCs can also differentiate into long tissue themselves, so that is one thing they can do.
42:57.278 --> 43:15.696
[SPEAKER_01]: They do differentiate, and they've shown MSC's differentiation, not just, you know, when people think of MSCs, yes, okay, you can show that they're MSCs by seeing whether or not they can differentiate into fat, muscles or cartilage, but that's, you know, that's just one
43:16.013 --> 43:27.164
[SPEAKER_01]: Potential, especially if you use adult MSCs, but we use younger MSCs, they have a lot more potential to differentiate into different cell types, including neurons, including liver cells.
43:27.184 --> 43:31.035
[SPEAKER_01]: And so here we see long cells, you know, epithelios tissue.
43:31.015 --> 43:42.386
[SPEAKER_01]: And MICs can also prevent certain responses that's driven by the viral injury by educating macrophages in the long environment.
43:42.807 --> 43:49.453
[SPEAKER_01]: So I guess educating them to go into a more pro-endogenic type.
43:50.094 --> 43:57.681
[SPEAKER_01]: And the macrophages will in turn, after being educated, will increase the secretion of various growth factors.
43:57.661 --> 44:00.133
[SPEAKER_01]: to promote tissue regeneration.
44:00.253 --> 44:03.047
[SPEAKER_01]: So they're telling other cells to do their work.
44:03.629 --> 44:06.523
[SPEAKER_01]: And MSC's can also adopt
44:07.027 --> 44:12.114
[SPEAKER_01]: certain types when they are exposed to inflammatory cytokines.
44:12.535 --> 44:15.198
[SPEAKER_01]: So there are two types of MSEs.
44:15.579 --> 44:16.901
[SPEAKER_01]: There's type 1 and type 2.
44:17.301 --> 44:21.367
[SPEAKER_01]: So type 2 is more untimed flammatory.
44:21.667 --> 44:29.779
[SPEAKER_01]: So when they are affected by all this inflammation, they can go into this more untimed flammatory phenotype, which is very interesting.
44:30.740 --> 44:35.667
[SPEAKER_01]: So this is one case study.
44:35.647 --> 44:50.383
[SPEAKER_01]: history of excellent health but had COVID infection in 2022 in September that lasted for 15 days right no big deal and then in October in November she noticed significant fatigue and headache that wasn't going away.
44:50.583 --> 44:59.933
[SPEAKER_01]: So what happened was that she received two weeks of IV therapy that included ozone therapy
44:59.913 --> 45:12.337
[SPEAKER_01]: and exosomium infusion, so there's a lot of study done in exosome, so this is one way the stem cells work, so it's through these exosome secretions.
45:12.698 --> 45:16.605
[SPEAKER_01]: So these exosomium infusions were given at one CC,
45:16.585 --> 45:21.898
[SPEAKER_01]: along with, you know, after ozone therapy, one C.C.
45:21.998 --> 45:25.426
[SPEAKER_01]: along with Myers and glutathione, IV push.
45:26.208 --> 45:31.220
[SPEAKER_01]: And the treatment, you know, so these were done twice a week.
45:32.202 --> 45:34.628
[SPEAKER_01]: And, and, and,
45:35.671 --> 45:45.067
[SPEAKER_01]: And the one week, first week, she was able to run errands already, and within six to eight weeks, she reached 100% recovery.
45:45.808 --> 45:49.715
[SPEAKER_01]: So two weeks of twice a week, so that means she did four sessions total.
45:50.296 --> 45:59.552
[SPEAKER_01]: And then there's some other adjunct treatment, including low dose now track zone, and nebulization of hydrogen peroxide, gluthion, and kintong water.
45:59.532 --> 46:16.140
[SPEAKER_01]: So, that's the case, you know, I welcome you, any of you have other cases, you know, any other successes, you know, I'll love to hear about that, but yeah, so this patient reached really, you know, good results with four sessions.
46:16.120 --> 46:20.707
[SPEAKER_01]: And then just last thing, I just want to talk a little bit about the tissue source.
46:21.188 --> 46:28.741
[SPEAKER_01]: You can use bone marrow or fat when local court to get stem cells, so they are all good candidates.
46:29.602 --> 46:40.660
[SPEAKER_01]: And I just want to talk about am partial to end local court stem cells because I have dumped into the subject for so long when I first started seven years ago in this whole stem cell.
46:40.640 --> 46:41.361
[SPEAKER_01]: field.
46:41.802 --> 46:43.985
[SPEAKER_01]: I just wanted to find the best source for patients.
46:44.205 --> 46:48.151
[SPEAKER_01]: I don't care what it is, I don't care what kind of training I have to do, what kind of equipment I have to acquire.
46:48.591 --> 46:50.314
[SPEAKER_01]: I just want whatever that works the best.
46:50.614 --> 47:01.270
[SPEAKER_01]: So I dealt really deep into different studies, looking at different sources, and so I have actually have, you know, I put my lecture on YouTube is called ROMC's Created Equal.
47:01.610 --> 47:03.593
[SPEAKER_01]: So I went into,
47:03.573 --> 47:05.979
[SPEAKER_01]: lots of studies comparing these tissue sources.
47:06.320 --> 47:12.394
[SPEAKER_01]: So I do believe that the local court source is superior because of many reasons I listed there.
47:12.735 --> 47:19.050
[SPEAKER_01]: So first of all, high cell viability and they have great abilities to proliferate.
47:19.030 --> 47:25.564
[SPEAKER_01]: They have anti-inflammatory, higher anti-inflammatory activities, more new regulatory capabilities.
47:26.145 --> 47:28.690
[SPEAKER_01]: They have promote more endogenesis.
47:29.432 --> 47:30.935
[SPEAKER_01]: They're more neuroprotective.
47:31.456 --> 47:33.982
[SPEAKER_01]: They can differentiate into more cell types.
47:34.382 --> 47:37.950
[SPEAKER_01]: They have longer telomeres and higher telomerase activity levels.
47:37.930 --> 47:40.354
[SPEAKER_01]: And they have more generations left.
47:40.534 --> 47:42.076
[SPEAKER_01]: They're just gonna be around longer.
47:42.116 --> 47:45.101
[SPEAKER_01]: And they have less potential to promote cancer growth.
47:45.121 --> 47:46.703
[SPEAKER_01]: So that's the one I kind of hinted at.
47:47.444 --> 47:54.395
[SPEAKER_01]: There was one study looking at fat derived MIC's versus local core derived MIC's.
47:54.415 --> 47:58.521
[SPEAKER_01]: They put these two types of MIC's next to glioblastoma.
47:58.501 --> 48:02.127
[SPEAKER_01]: So this very real-enformed brain cancer cells.
48:02.147 --> 48:08.477
[SPEAKER_01]: They put them next to these cancer cells, either in a petro-dish or on the live animal's body.
48:08.818 --> 48:16.510
[SPEAKER_01]: So in both cases, the fat derived MICs made the cancer grow more and more.
48:16.608 --> 48:21.298
[SPEAKER_01]: yet then local core derived MICs make the cancer shrink and go away.
48:21.699 --> 48:30.498
[SPEAKER_01]: So this is another reason why I think it's important as a provider, you know, I want to give people treatments not only effective, but also safe.
48:30.799 --> 48:34.667
[SPEAKER_01]: The last thing is I think as a precaution,
48:34.647 --> 48:49.192
[SPEAKER_01]: You know, probably avoiding the vaccine, you know, as first donor that have been vaccinated, you know, because there are too many unknown aspects, you know, this could be, you know, go down the whole rabbit hole about this subject.
48:49.612 --> 48:55.963
[SPEAKER_01]: But the product I use, and I insist on, will be from,
48:55.943 --> 48:57.005
[SPEAKER_01]: young healthy mothers.
48:57.485 --> 49:00.429
[SPEAKER_01]: These are all U.S. based mothers that have never been vaccinated.
49:00.510 --> 49:06.138
[SPEAKER_01]: So, yes, it's getting harder and harder, but that's one of the principles I have.
49:06.178 --> 49:11.025
[SPEAKER_01]: So, like Dr. Frank mentioned, I have booth chart biologics.
49:11.325 --> 49:12.867
[SPEAKER_01]: So, you're welcome to come talk to me.
49:13.649 --> 49:15.892
[SPEAKER_01]: But that is one philosophy I have.
49:15.912 --> 49:21.580
[SPEAKER_01]: And you know that I'm going to stick to it because I'm not willing to put that in my own body or my patient's body.
49:21.560 --> 49:24.952
[SPEAKER_01]: or anybody's body, anyone other doctors at trading.
49:24.992 --> 49:26.417
[SPEAKER_01]: So it's important to me.
49:27.622 --> 49:31.134
[SPEAKER_01]: So that's, yeah, I just think there are too many things that are unknown.
49:31.717 --> 49:32.700
[SPEAKER_01]: So that's it.
49:36.072 --> 49:38.074
[SPEAKER_01]: Thank you for listening to this episode.
49:38.595 --> 49:40.057
[SPEAKER_01]: Hope you enjoy the content.
49:40.758 --> 49:43.861
[SPEAKER_01]: And if so, please rate and follow this podcast.
49:44.182 --> 49:53.373
[SPEAKER_01]: To learn about everything I do, including my memoir Tiger of Beijing, you can go to www.doctorjoykong.com.
49:54.153 --> 49:57.598
[SPEAKER_01]: And if you like to reach me, simply send in a contact form.
49:58.378 --> 50:02.023
[SPEAKER_01]: You can also subscribe to my YouTube channel Joy Kong MD.
50:02.844 --> 50:03.885
[SPEAKER_01]: I'll see you next time.
00:00.031 --> 00:01.413
[SPEAKER_01]: health is very complex.
00:01.593 --> 00:04.957
[SPEAKER_01]: Our body have so many things that's happening all like once.
00:05.037 --> 00:07.860
[SPEAKER_01]: We're dealing with a web, the web of biology.
00:08.080 --> 00:14.047
[SPEAKER_01]: The stem cells can go in and provide some fundamental shifts, but it's not covering all ground.
00:14.347 --> 00:22.577
[SPEAKER_01]: I think it would be naive to think just because stem cell therapy is amazing that I can just give you one treatment and then expect everybody to do amazingly well.
00:22.617 --> 00:29.565
[SPEAKER_01]: The person could be deficient in amino acids and minerals
00:29.545 --> 00:32.388
[SPEAKER_01]: I always try to give people a realistic expectation.
00:32.609 --> 00:35.632
[SPEAKER_01]: I'm hoping for miracles, but I'm not expecting miracles.
00:35.952 --> 00:40.217
[SPEAKER_01]: And then there may be a regiment that's needed, like anything in medicine.
00:40.317 --> 00:45.884
[SPEAKER_01]: There's a dose, there's a regimen, because we're dealing with biology, the biology has this own rhythm.
00:46.044 --> 00:53.492
[SPEAKER_01]: I tell people just like, when you're sick with infection, you don't take your whole bottle of antibiotics, expecting that I'm cured, right?
00:53.753 --> 00:58.438
[SPEAKER_01]: You take it every four to six hours because you're respecting the rhythm of biology.
00:58.418 --> 01:01.183
[SPEAKER_01]: Welcome to the Dr. Joy Kong podcast.
01:01.203 --> 01:08.194
[SPEAKER_01]: This is where I have a chance to share with you some of the latest developments in the space of holistic health, longevity, and wellness.
01:08.615 --> 01:15.447
[SPEAKER_01]: I've always honored intellectual curiosity and scientific rigor, combined with real world practicality.
01:15.767 --> 01:20.175
[SPEAKER_01]: My goal is that what you learn here will help you live longer and live better.
01:20.475 --> 01:22.198
[SPEAKER_01]: Hope you enjoy the journey with me.
01:23.005 --> 01:41.507
[SPEAKER_00]: All right, so Joy Kong, MD, is a UCLA train triple board certified, triple board, wow, certified physician, American board of psychiatry and neurology, American board of addiction, medicine, and American board anti-aging and regenerative medicine.
01:42.348 --> 01:46.212
[SPEAKER_00]: I'm pretty sure you don't want to take any more tests at this point.
01:46.192 --> 02:01.323
[SPEAKER_00]: but she's the president of the Thia Center for regenerative medicine in Los Angeles, where she specializes in stem cell treatments to improve the functions of diverse organ systems in the body as well as for preventive and endless wellness purposes.
02:01.343 --> 02:05.972
[SPEAKER_00]: And I will say that, you know, I like to consult with her periodically, because I don't.
02:05.952 --> 02:09.557
[SPEAKER_00]: You know, I have a like a super duper grass once themselves.
02:10.077 --> 02:28.821
[SPEAKER_00]: She does some very interesting unique things with her stem cells She's also the medical director for avalanche surgery center She oversees all regenerative medicine treatments and she founded the American Academy of Integrated cell therapy where she provides training
02:28.801 --> 02:34.915
[SPEAKER_00]: I probably need to go to that course clinical evidence and aspects of clinical practice of stem cell treatments.
02:34.935 --> 02:46.101
[SPEAKER_00]: She has developed unique stem cell treatment protocols, including patent pending intranasal and needle-free male and female sexual wellness protocols.
02:46.081 --> 02:56.046
[SPEAKER_00]: She's the founder and CEO of Chiara Biologics, a company dedicated to providing cutting edge regenerative medicine products in the U.S. and the rest of the globe.
02:56.948 --> 03:02.723
[SPEAKER_00]: She's also a board member of the American Association of STEM Self-Ausitions and is a proponent.
03:02.703 --> 03:12.137
[SPEAKER_00]: of conducting high-quality clinical research and is a medical consultant for stem cell research projects to be conducting projects.
03:12.298 --> 03:17.385
[SPEAKER_00]: Okay, Dr. Kong is a firm believer in the therapeutic potentials of self-therapies.
03:17.405 --> 03:26.239
[SPEAKER_00]: She's lectured nationally and internationally on stem cell treatments and has exchanged ideas with a top stem cell scientists from around the globe.
03:26.719 --> 03:29.824
[SPEAKER_00]: So Dr. Kong, please give
03:38.292 --> 03:41.678
[SPEAKER_01]: Thank you so much, Dr. Frank, for such a wonderful introduction.
03:41.798 --> 03:43.220
[SPEAKER_01]: I'm so privileged to be here.
03:43.240 --> 03:58.365
[SPEAKER_01]: I have a really particular fondness for this crowd, because you guys are probably some of the most adventures and courageous people, because you believe in ozone therapy, you believe in the modality.
03:58.866 --> 03:59.727
[SPEAKER_01]: That's
03:59.707 --> 04:06.820
[SPEAKER_01]: effective and it's safe and you're willing to use it despite certain oppositions.
04:07.041 --> 04:10.327
[SPEAKER_01]: So I really love this group of doctors.
04:11.208 --> 04:17.300
[SPEAKER_01]: So today I'm going to be talking about regenerative medicine in autoimmune diseases and long COVID.
04:18.341 --> 04:19.183
[SPEAKER_01]: So
04:19.163 --> 04:23.068
[SPEAKER_01]: Use of stem cell therapy is very broad.
04:23.308 --> 04:26.752
[SPEAKER_01]: You know, it's broad range of possibilities.
04:26.993 --> 04:31.298
[SPEAKER_01]: So autoimmune diseases, one of the places where stem cell therapy really shines.
04:31.879 --> 04:42.572
[SPEAKER_01]: So I'm going to go over a few disease categories then end with lung COVID, which really is kind of a branch of this autoimmune dysregulation.
04:42.552 --> 04:53.424
[SPEAKER_01]: The traditional route of using stem cell therapy for autoimmune disease is using hematopuatic stem cell therapy, which are usually from bone marrow.
04:53.464 --> 04:58.110
[SPEAKER_01]: So that's the first stem cell therapy is using the bone marrow.
04:58.130 --> 04:58.310
[SPEAKER_01]: Right?
04:58.330 --> 05:02.675
[SPEAKER_01]: Bone marrow transplant people, you know, in the 60s, they didn't know they were doing stem cell therapy.
05:02.695 --> 05:04.837
[SPEAKER_01]: They were just transplanting bone marrow.
05:04.857 --> 05:08.001
[SPEAKER_01]: But then later on, we realized that that's actually stem cell therapy.
05:08.461 --> 05:09.943
[SPEAKER_01]: So using
05:09.923 --> 05:15.910
[SPEAKER_01]: a donor's bone marrow, that's one of the first ways of doing stem cell therapy.
05:17.492 --> 05:25.681
[SPEAKER_01]: But that kind of treatment, so the hematopuatic stem cells, those are the major, one of the major stem cell types in the bone marrow.
05:26.101 --> 05:34.851
[SPEAKER_01]: But that has a lot of potentials for rejection, so you need immune, suppressive medications, and that can really take a toll on patients.
05:34.831 --> 05:44.263
[SPEAKER_01]: Or you can use your own, but that is linked to a lot of morbidity and mortality, including infections and recurrence is pretty common.
05:44.784 --> 05:51.492
[SPEAKER_01]: So MIC is kind of as the newer cell type on the block and they realize, oh, oh my goodness.
05:51.512 --> 05:56.279
[SPEAKER_01]: So there's this particular cell type that's derived from the mesenchymal lineage.
05:57.921 --> 06:02.847
[SPEAKER_01]: But they have very little surface markers and mark the mesophoren.
06:02.827 --> 06:15.425
[SPEAKER_01]: and they have this immigulating properties so you can give it to people sometimes completely unmatched and people are doing great, you know, having all kinds of therapeutic responses.
06:15.946 --> 06:26.781
[SPEAKER_01]: So, yeah, so even with mismatch, HLA mismatch, they can hold me into the damage tissue and exert clinical benefit and the benefit tends to be much more sustained.
06:26.962 --> 06:28.564
[SPEAKER_01]: This is the Pylice study.
06:28.544 --> 06:34.761
[SPEAKER_01]: on allergenic MSEs for refractory lupus, SLE.
06:34.781 --> 06:40.677
[SPEAKER_01]: So what's interesting is that all immune diseases have been proposed as stem cell disorders.
06:41.579 --> 06:44.848
[SPEAKER_01]: And there are functional abnormalities
06:44.828 --> 06:59.852
[SPEAKER_01]: in the bone marrow MSCs, in patients with lupus, including defectiveness, in cytokine secretion, with the downregulation of different cytokines and RNA expressions.
07:00.573 --> 07:05.862
[SPEAKER_01]: And here's a study actually looking at 16 patients.
07:05.882 --> 07:08.406
[SPEAKER_01]: And they saw,
07:08.386 --> 07:18.499
[SPEAKER_01]: by using a local core derived MSEs that I one month after the treatment, these people has significant decrease in disease severity.
07:19.120 --> 07:24.788
[SPEAKER_01]: And they also showed that these loopous patients had improved levels of disease markers.
07:25.829 --> 07:31.677
[SPEAKER_01]: They improved their renal function, and clinically there seemed to be a shift
07:31.657 --> 07:47.880
[SPEAKER_01]: more of a balance between the TH-1 and TH-2 sites of the immune system and increase in T-Rex cells and the significant reduction in disease activity was achieved in all these 16 patients with no recurrence in three years.
07:48.140 --> 07:49.883
[SPEAKER_01]: So this is a very successful study.
07:50.143 --> 07:57.674
[SPEAKER_01]: So this one is another study looking at 40 patients and they use expanded on local core derived MICs.
07:58.395 --> 08:01.579
[SPEAKER_01]: They were giving these patients
08:01.559 --> 08:28.292
[SPEAKER_01]: on day zero and seven, and there were no averse reactions, so major clinical response was achieved in about a third of the patients, and there are also 40 percent of patients who had no clinical response, and at nine months the relapse rate was 12.5, at 12 months, 6.7, so they think that likely these people would require re-infusion in six months, so some kind of booster shot, so
08:28.272 --> 08:30.475
[SPEAKER_01]: you know, we do see this clinically.
08:31.577 --> 08:33.620
[SPEAKER_01]: There are people who are doing amazingly well.
08:34.622 --> 08:41.893
[SPEAKER_01]: I've seen people who have complete remission to the point where all their markers are normal.
08:41.933 --> 08:47.461
[SPEAKER_01]: So basically they are disease-free, but there are also people who need more infusion.
08:47.501 --> 08:51.327
[SPEAKER_01]: I think, you know,
08:51.307 --> 08:55.514
[SPEAKER_01]: kind of functional medicine crowd, that we know the health is very complex.
08:55.735 --> 09:00.884
[SPEAKER_01]: Our body is, you know, have so many things that's happening all like once.
09:00.924 --> 09:03.789
[SPEAKER_01]: We're dealing with a web, the web of biology.
09:04.230 --> 09:08.978
[SPEAKER_01]: So the stem cells can go in and provide some fundamental shifts.
09:08.958 --> 09:11.763
[SPEAKER_01]: in patients, but it's not covering all ground.
09:12.064 --> 09:28.215
[SPEAKER_01]: I think it would be naive to think just because stem cell therapy is amazing that I can just give you one treatment and then expect everybody to do an amazing new well because a person could be deficient in amino acids, could be deficient in minerals, could be, you know, hormonally,
09:28.195 --> 09:46.542
[SPEAKER_01]: depleted or have toxicity, so I always try to give people a realistic expectation that I'm not expecting miracles, I'm hoping for miracles, but I'm not expecting miracles, and then there may be a regiment that's needed, we may be looking at three treatments within, you know.
09:46.522 --> 09:59.494
[SPEAKER_01]: four to six months, so I want people to be prepared mentally and not expect this to be a miracle because like anything in medicine, it does.
09:59.754 --> 10:04.125
[SPEAKER_01]: There's a regimen because we're dealing with biology, biology has its own
10:04.105 --> 10:04.947
[SPEAKER_01]: this own rhythm.
10:05.207 --> 10:13.242
[SPEAKER_01]: You know, I tell people just like when you're sick with infection, you don't take your whole bottle of antibiotics, expecting that I'm cured, right?
10:13.503 --> 10:17.972
[SPEAKER_01]: You take it every four to six hours because you're respecting the rhythm of biology.
10:18.232 --> 10:20.376
[SPEAKER_01]: There's a way of helping the body repair.
10:20.797 --> 10:22.941
[SPEAKER_01]: Here's another example.
10:22.921 --> 10:27.548
[SPEAKER_01]: just looking at a secondary pathology from patients with lupus.
10:28.029 --> 10:30.132
[SPEAKER_01]: So, this is secondary osteoporosis.
10:30.953 --> 10:39.025
[SPEAKER_01]: So, what's interesting is that one of the mechanisms of the MSC's benefits could be through IL-17 suppression.
10:39.085 --> 10:45.174
[SPEAKER_01]: And that IL-17 is an inflammatory cytokine that's implicated in autoimmune diseases.
10:45.655 --> 10:51.544
[SPEAKER_01]: So, and these can be defective in the recipient's bone marrow.
10:51.524 --> 11:03.631
[SPEAKER_01]: So what happens is that the transplantation of MICs can promote healthy bone metabolism by establishing a new balance between the osteoplasts and osteoclasts.
11:04.653 --> 11:10.326
[SPEAKER_01]: And so here's another study using
11:10.525 --> 11:12.226
[SPEAKER_01]: and local cord MICs.
11:12.727 --> 11:20.073
[SPEAKER_01]: So they do have profound inhibitory effect on these particular cells, fibril blasts like synovial sites.
11:20.774 --> 11:30.042
[SPEAKER_01]: And inhibitory effect on these cells and then on the overactivation of T cells can really help these rheumatoid arthritis patients.
11:30.062 --> 11:32.204
[SPEAKER_01]: So we're moving onto rheumatoid arthritis.
11:32.764 --> 11:39.570
[SPEAKER_01]: One of the ways they induce such effect is by inducing T-rexal activation.
11:39.550 --> 11:43.518
[SPEAKER_01]: and T-Rex play a very important role in South Immune tolerance.
11:43.979 --> 11:56.243
[SPEAKER_01]: So, on Blocal Court, M.I.C.s can again shift the TH-1 TH-2 balance, and the infusion, systemic infusion, was able to reduce disease severity in mouse.
11:56.223 --> 12:08.396
[SPEAKER_01]: It's just a sight note, you know, people say, okay, so, you know, I give one person's themselves to another person is not a perfect match or the South's gonna stay, so that's a question that's been asked many times.
12:08.436 --> 12:10.679
[SPEAKER_01]: I've asked many experts from the field.
12:11.079 --> 12:19.548
[SPEAKER_01]: Some say, no, it's impossible for one person's self to say another, which is not true because bone marrow transplant, you know, is very successful.
12:19.648 --> 12:25.875
[SPEAKER_01]: And some say, yeah, it's very small
12:25.855 --> 12:27.638
[SPEAKER_01]: can stay in an animal's body.
12:27.678 --> 12:29.441
[SPEAKER_01]: So these are different species.
12:29.941 --> 12:34.589
[SPEAKER_01]: So even with that much difference in a Charlie marker, cells can stay.
12:34.609 --> 12:37.614
[SPEAKER_01]: So I think there's a really good chance that cells can stay.
12:37.634 --> 12:44.084
[SPEAKER_01]: And when you use younger cells, the cells have a better tendency to adapt to the host environment.
12:44.564 --> 12:50.614
[SPEAKER_01]: So if you are transplanting bone marrow stem cells, even if it's perfectly matched,
12:50.594 --> 12:51.876
[SPEAKER_01]: Perfect H. Ali matching.
12:52.176 --> 12:53.538
[SPEAKER_01]: There's still a chance rejection.
12:53.978 --> 13:00.787
[SPEAKER_01]: But if you're using young and local core blood stem cell, and local core blood composition is very similar to bone marrow composition.
13:01.187 --> 13:05.973
[SPEAKER_01]: So in those cases, there's very little rejection, even when it's completely unmatched.
13:06.294 --> 13:11.100
[SPEAKER_01]: So that's how different young cells are and versus older cells.
13:11.561 --> 13:14.584
[SPEAKER_01]: And when cells are younger, they get into the whole spotty.
13:14.885 --> 13:18.289
[SPEAKER_01]: There's much better chance that they will adapt.
13:18.269 --> 13:27.173
[SPEAKER_01]: So when you're older, it's almost like, you know, they've got their own thing, they have their own, you know, ideas that their own, you know, ways of doing things, some things are set.
13:27.454 --> 13:29.760
[SPEAKER_01]: But when they're younger, they're more malleable.
13:30.061 --> 13:33.510
[SPEAKER_01]: They're more able to adapt the host environment.
13:33.828 --> 13:37.594
[SPEAKER_01]: So in this study, they saw a good response in animal model.
13:37.995 --> 13:45.667
[SPEAKER_01]: And here's a fairly large study for humans, 170 two patients with active room to their arthritis.
13:46.489 --> 13:54.161
[SPEAKER_01]: And they had two groups, so they used the disease modifying anti-rumatic drugs in both groups.
13:54.982 --> 13:59.650
[SPEAKER_01]: One, they added placebo, the other one, they added a local court MSCs.
13:59.630 --> 14:06.484
[SPEAKER_01]: So only 40 million cells per infusion and they were able to see that after two weeks.
14:07.240 --> 14:13.267
[SPEAKER_01]: post-inthusion, there's significant remission in the group that used MSEs.
14:14.188 --> 14:17.913
[SPEAKER_01]: And the improvement was not seen in the group that had placebo.
14:18.634 --> 14:24.220
[SPEAKER_01]: And joint pain and swelling were alleviated within 12 hours and maintained throughout the study.
14:24.641 --> 14:25.862
[SPEAKER_01]: And that's pretty common.
14:26.002 --> 14:27.264
[SPEAKER_01]: I had one patient.
14:27.704 --> 14:33.231
[SPEAKER_01]: She was a cervical nurse and she was
14:33.211 --> 14:37.216
[SPEAKER_01]: begin to have rheumatoid arthritis symptoms, and she was not able to work.
14:38.258 --> 14:44.085
[SPEAKER_01]: So during the infusion, this is within, you know, 30 minutes of starting the infusion.
14:44.265 --> 14:49.051
[SPEAKER_01]: In the middle of the infusion, and she did this, she closed her fist, and she started crying.
14:49.652 --> 14:53.397
[SPEAKER_01]: And she said, I have not been able to close my fist for two months.
14:53.377 --> 15:01.510
[SPEAKER_01]: So it can happen that fast, and I hear that quite a bit, you know, swelling within a couple hours, the swelling the hands go down.
15:01.610 --> 15:04.494
[SPEAKER_01]: So the end-time flammatory effect can happen very fast.
15:04.795 --> 15:08.841
[SPEAKER_01]: So I tell people that there are different stages of healing with stem cell therapy.
15:09.262 --> 15:11.385
[SPEAKER_01]: So when people say, when can I expect benefit?
15:11.365 --> 15:16.274
[SPEAKER_01]: Well, let's look at what the cells are doing and what are the stages.
15:16.554 --> 15:19.940
[SPEAKER_01]: The first stage is the anti-inflammatory stage, so that can happen very fast.
15:20.281 --> 15:26.472
[SPEAKER_01]: To the point where I treated Alzheimer's patient, she was so stuck.
15:26.452 --> 15:31.059
[SPEAKER_01]: in her, I think it's the neuro-inflammation that she had not been able to feed herself for a month.
15:31.479 --> 15:32.401
[SPEAKER_01]: She was not eating.
15:32.421 --> 15:33.703
[SPEAKER_01]: The food would be in front of her.
15:34.103 --> 15:35.285
[SPEAKER_01]: She would not her brain.
15:35.345 --> 15:36.887
[SPEAKER_01]: And there was no signal coming through.
15:36.927 --> 15:39.871
[SPEAKER_01]: She could not pick up a knife and fork, even though she's hungry.
15:39.952 --> 15:40.392
[SPEAKER_01]: She couldn't.
15:40.913 --> 15:44.238
[SPEAKER_01]: But the next day after the Samsung treatment, the food was in front of her.
15:44.278 --> 15:46.341
[SPEAKER_01]: She picked up knife and fork, and she's to set her up.
15:46.401 --> 15:48.844
[SPEAKER_01]: And her husband was looking at her, you know, in shock.
15:48.864 --> 15:51.328
[SPEAKER_01]: And she looked up at him, it's like, what's your problem?
15:51.308 --> 16:09.942
[SPEAKER_01]: So, yeah, so it can happen that fast and that's an anti-inflammatory effect, but the second stage is the tissue rebuilding and that takes time, so whatever you're trying to do, you know, if it's musculoskeletal issue or systemic autoimmune issue or, you know, any organ repair,
16:09.922 --> 16:30.630
[SPEAKER_01]: there is a stage of slowly the cells is going to tell the local tissue to start to divide or the cells could differentiate locally and that takes time and that takes weeks to months time and the last stage is the genetic modification because the cells do send out microRNAs which could
16:30.610 --> 16:36.464
[SPEAKER_01]: go into the cell nucleus and make genetic changes and produce long lasting benefits.
16:36.484 --> 16:48.754
[SPEAKER_01]: And these cells also can conduct mitochondria transfer, so it can give the recipient cells fresh new mitochondria, so elevating the cellular energy, and that could have much longer benefit.
16:48.734 --> 16:52.479
[SPEAKER_01]: Another condition psoriasis that I've seen good results clinically.
16:52.919 --> 17:02.031
[SPEAKER_01]: This is animal study, the TH17 cells, and their related cytokines are pretty important in the pathogenesis of psoriasis.
17:02.771 --> 17:09.480
[SPEAKER_01]: And MSC's can inhibit the TH17 cells and induce the T-rex cells.
17:10.181 --> 17:18.471
[SPEAKER_01]: And they've shown some defect in the patient's cellular composition.
17:18.451 --> 17:27.109
[SPEAKER_01]: they could, you know, the MSC's from their skin, their ability to inhibit the T-cell proliferation is much decreased.
17:27.630 --> 17:36.088
[SPEAKER_01]: So that's another reason, you know, sometimes when you try to use a person's own stem cells, you know, genetically they're just not as...
17:36.068 --> 17:36.969
[SPEAKER_01]: as effective.
17:37.129 --> 17:41.795
[SPEAKER_01]: You know, there's something that's different in the disease patients cells.
17:42.235 --> 17:46.580
[SPEAKER_01]: It's another reason that I'm a proponent at using healthy donor sources.
17:46.720 --> 17:47.841
[SPEAKER_01]: There are many other reasons.
17:47.902 --> 17:52.867
[SPEAKER_01]: I have a lecture, I've given in a few conferences about different cell sources.
17:53.528 --> 17:57.472
[SPEAKER_01]: It's not just that these cells are young and healthy.
17:58.213 --> 17:59.214
[SPEAKER_01]: They're more potent.
17:59.635 --> 18:05.822
[SPEAKER_01]: They seek to create more anti-inflammatory
18:05.802 --> 18:07.364
[SPEAKER_01]: They're also our safer.
18:07.424 --> 18:09.326
[SPEAKER_01]: So I'll talk a little bit about that later.
18:09.707 --> 18:12.310
[SPEAKER_01]: So this is study on severe psoriasis.
18:12.750 --> 18:27.287
[SPEAKER_01]: So the background was that, you know, so back in 2002, four patients under went autologues, hematopoedic stem cell treatments, so using cells from their own bone marrow re-infused and they all relapsed within 21 months.
18:27.267 --> 18:38.042
[SPEAKER_01]: And then, so in the literature, between 1990 and 2002, nine patients had allergenic, the hematopoietics stem cell transplant.
18:38.062 --> 18:45.612
[SPEAKER_01]: The longest time for remission was four years and there's one patient actually remained.
18:46.093 --> 18:52.482
[SPEAKER_01]: So there's a surratic rash, the rash remained absent for 17 years after two treatments.
18:52.462 --> 19:01.617
[SPEAKER_01]: And this case study was a 29-year-old guy with extensive psoriasis in age 13 and also polyarthritis.
19:02.077 --> 19:11.753
[SPEAKER_01]: So he later on found out he also had golden-duced a plastic anemia and he received
19:11.733 --> 19:18.779
[SPEAKER_01]: you know, and that point, you know, for the NEMIA, not, you know, I'm sure that they weren't doing it thinking that they were trying to treat psoriasis.
19:19.420 --> 19:41.740
[SPEAKER_01]: So, he received alugienic, he metapuetic stem cells from a, you know, compatible female sibling, and they, there was some acute graft versus halts reaction, so they had to use medications, you know, including steroid for seven months,
19:41.720 --> 19:46.245
[SPEAKER_01]: And so I'm going to move on to inflammatory bowel disease.
19:47.693 --> 19:54.799
[SPEAKER_01]: So stensile transplant has definitely been used for inflammatory bowel diseases.
19:55.360 --> 20:01.886
[SPEAKER_01]: And again, you know, the, where I started was the metabolic stem cells and they used autologous stem cells.
20:02.526 --> 20:17.700
[SPEAKER_01]: The first study, 900 patients, so that they did a cohort study, the survival rate of using a person's own the metabolic stem cells was 85% at five years.
20:17.680 --> 20:24.752
[SPEAKER_01]: And 30% had complete response, but the problem is, again, these people are on chemotherapy regimen.
20:25.052 --> 20:31.162
[SPEAKER_01]: They had to take antibiotics and steroid, so that's really not an ideal kind of treatment.
20:31.824 --> 20:40.498
[SPEAKER_01]: And they could also use allergenic hematopoietics stem cells, which usually means bone marrow transplant.
20:40.478 --> 20:42.942
[SPEAKER_01]: unless they were using um, local core blood cells.
20:43.042 --> 20:45.685
[SPEAKER_01]: But I think these are our bone marrow transplant patients.
20:46.146 --> 20:55.820
[SPEAKER_01]: So the allergenic hematopoedic stem cell transplant can potentially correct the underlying disease genetically, right, using a healthy donor cells.
20:56.261 --> 21:02.149
[SPEAKER_01]: But that also is associated with complication and mortality rate, because
21:02.129 --> 21:07.257
[SPEAKER_01]: He might have poetic stem cell still, there's a chance and tendency for mismatch.
21:07.978 --> 21:13.046
[SPEAKER_01]: And people have to use, again, use certain medications to help prevent that.
21:14.148 --> 21:21.359
[SPEAKER_01]: This study, even using on vocal core blood, there's still some chance, because on vocal core blood have almost no MSCs in it.
21:21.399 --> 21:23.362
[SPEAKER_01]: And well, it has a very tiny fraction.
21:23.723 --> 21:25.926
[SPEAKER_01]: So bone marrow has about 0.1,
21:25.906 --> 21:32.958
[SPEAKER_01]: A point zero one to point one percent MSEs in the in the bone marrow self and very similar in the and local core blood.
21:32.998 --> 21:41.433
[SPEAKER_01]: So you have very few MSEs which modulated immune system prevent graft versus host disease and really help to calm the system.
21:41.473 --> 21:49.888
[SPEAKER_01]: So when you have very little MSEs in in the core blood or bone marrow, you have much higher chance of having these reactions.
21:49.868 --> 22:02.785
[SPEAKER_01]: And this is why Joanne Kersberg, who is in Duke University, she's doing autism study using a local core blood, is much easier and I think safer and more effective than bone marrow transplant.
22:02.805 --> 22:15.943
[SPEAKER_01]: But she still has to pre-medicate all these kids with these medications and steroid, which I'm still not a fan of when there's ready source of mesenchymal stem cells that can really prevent these kind of rejections.
22:15.923 --> 22:18.708
[SPEAKER_01]: Then we come to mesenchymostensile transplantation.
22:18.728 --> 22:24.678
[SPEAKER_01]: So these are the newer treatments, because all we knew were bone marrow before, but now we know much better.
22:25.620 --> 22:28.645
[SPEAKER_01]: So you can do local injection of these mesenchymostensiles.
22:29.086 --> 22:36.819
[SPEAKER_01]: So this study, they looked at Paranofistrolus, and they were using 30 million MSCs.
22:37.681 --> 22:40.125
[SPEAKER_01]: And that was more...
22:40.105 --> 22:43.269
[SPEAKER_01]: If efficacious, then 10 million versus 90 million.
22:43.309 --> 22:44.290
[SPEAKER_01]: So it's very interesting.
22:44.330 --> 22:50.757
[SPEAKER_01]: I've seen that quite a bit that there's a dose response, and it doesn't mean more is better.
22:50.917 --> 22:55.383
[SPEAKER_01]: Sometimes you have a dose range that's much more ideal.
22:55.783 --> 22:59.127
[SPEAKER_01]: And if you go outside and range, maybe it's going to be less efficacious.
22:59.567 --> 23:00.849
[SPEAKER_01]: So pretty good.
23:00.889 --> 23:07.176
[SPEAKER_01]: The local injection of these stem cells, 85.7% success rate at week 12.
23:07.156 --> 23:09.900
[SPEAKER_01]: and the placebo only 33 percent.
23:10.381 --> 23:13.045
[SPEAKER_01]: And then you can also infuse these cells systemically.
23:13.505 --> 23:25.603
[SPEAKER_01]: So the first human trial was nine patients with active Crohn's and they received a IV bone marrow MSEs and three out of the 10 patients achieved clinical response by day 14.
23:25.583 --> 23:45.364
[SPEAKER_01]: You can also do IV, so there's an IV study IV bone marrow MSCs for moderate to severe Crohn's polymer study, 148 out of 207 patients reached remission in 28 days, which is pretty good, 148 out of 207.
23:45.344 --> 23:54.822
[SPEAKER_01]: But it's still not 207 and so clinically, you know, that's why I give I tell patients to, you know, temper your enthusiasm.
23:54.882 --> 23:58.970
[SPEAKER_01]: We're hopeful, but we're, is not guaranteed.
23:58.990 --> 24:00.253
[SPEAKER_01]: I mean, nothing's guaranteed in the medicine.
24:00.313 --> 24:05.142
[SPEAKER_01]: I will love to guarantee patients of complete healing, you know, that, you know, that 60, some,
24:05.122 --> 24:18.806
[SPEAKER_01]: patient and out of 207 to me is still a lot and it's you know it's very uncomfortable for me as as a clinician but but the fact is that I'm offering hope so much hope for those 148 patients.
24:19.207 --> 24:26.259
[SPEAKER_01]: Here's another study on Crohn's 82 patients diagnosed with Crohn's disease and they're on steroid maintenance.
24:26.439 --> 24:29.745
[SPEAKER_01]: They were given IV infusion.
24:29.725 --> 24:38.764
[SPEAKER_01]: So 41 of those were selected to receive infusion and you would see this dose range, you know, 1 million per kilo that's pretty standard.
24:39.225 --> 24:43.894
[SPEAKER_01]: But just remember that this dose range is established using expanded cells.
24:44.556 --> 24:48.544
[SPEAKER_01]: There's a lot of difference between unexpected and expanded cells.
24:48.524 --> 24:50.266
[SPEAKER_01]: There's a bit of a controversy.
24:50.306 --> 24:58.377
[SPEAKER_01]: There's people overseas who are doing a lot of these selling expansions and people seem to believe that more is better.
24:58.958 --> 25:05.227
[SPEAKER_01]: And even when the cells are not expanded, the same type of cells, more doesn't mean it's better.
25:05.607 --> 25:11.275
[SPEAKER_01]: The point you start to expand the cells, you're changing the characteristics of the cells.
25:11.255 --> 25:22.852
[SPEAKER_01]: unavoidable, especially after about three or four passages, but just remember when you expand the cells, you're putting them in the petri dish, you know, some kind of container in the incubator.
25:22.893 --> 25:32.487
[SPEAKER_01]: The cells that's well adapted to this environment, to this particular artificial environment, are going to be the cell that divide.
25:32.467 --> 25:35.110
[SPEAKER_01]: So, and they tend to gain more characteristics.
25:35.130 --> 25:43.480
[SPEAKER_01]: So, as they divide, they would express surface markers that show them their characteristics as whoever the donor is.
25:43.881 --> 25:49.968
[SPEAKER_01]: So, you will get these further differentiated cells that would express more surface markers.
25:50.308 --> 25:54.373
[SPEAKER_01]: They tend to bring about more rejection, type of reaction.
25:54.774 --> 25:59.379
[SPEAKER_01]: But also, they're losing capabilities and characteristics of the younger stem cells.
25:59.860 --> 26:02.423
[SPEAKER_01]: And many of them are no longer stem cells.
26:02.403 --> 26:10.619
[SPEAKER_01]: remember the dose calculation, and just because in a study says one million per kilo just remember these are expanded cells.
26:10.679 --> 26:14.085
[SPEAKER_01]: Native cells that have never been expanded will act differently.
26:14.506 --> 26:17.492
[SPEAKER_01]: So these people received infusions.
26:17.472 --> 26:20.059
[SPEAKER_01]: One week apart, four infusions total.
26:20.079 --> 26:24.911
[SPEAKER_01]: At 12 months, they show the disease scores decrease.
26:25.132 --> 26:28.520
[SPEAKER_01]: So the first one, it was the score decreased by 62.5%.
26:29.804 --> 26:33.473
[SPEAKER_01]: Compared to the placebo, that's 23.6%.
26:33.453 --> 26:40.783
[SPEAKER_01]: And another disease score is decreased by 3.4% compared to 1.2 in the control group.
26:41.464 --> 26:44.067
[SPEAKER_01]: And their steroid doses were decreased.
26:45.128 --> 26:50.676
[SPEAKER_01]: The placebo group only decreased the dose by 1.2 milligrams per day.
26:51.076 --> 26:54.060
[SPEAKER_01]: But this treated groups
26:54.040 --> 26:59.508
[SPEAKER_01]: were able to have the dose decrease by 4.2 milligrams.
26:59.528 --> 27:03.314
[SPEAKER_01]: So significant reduction in the amount of steroid that they have to use.
27:04.375 --> 27:08.601
[SPEAKER_01]: And here's just a visual of the changes at 12 months in their mucosa.
27:09.302 --> 27:13.969
[SPEAKER_01]: And then I've mentioned a couple of disease briefly, so sclerodoma.
27:14.310 --> 27:16.032
[SPEAKER_01]: So you know, the...
27:16.282 --> 27:24.274
[SPEAKER_01]: You know, because the certain diseases are more rare, the cases are, you know, a lot less so it's harder to find studies.
27:25.476 --> 27:30.865
[SPEAKER_01]: So we're still so new in the stem cell field, you know, as time goes on, there's gonna be more and more studies.
27:30.965 --> 27:34.410
[SPEAKER_01]: But this is the girl Derma, which is the top disease.
27:34.831 --> 27:38.356
[SPEAKER_01]: So they are using a local cord MSEs.
27:39.158 --> 27:41.361
[SPEAKER_01]: So they obtain these using collagenase.
27:41.341 --> 27:43.603
[SPEAKER_01]: and sales expansion.
27:43.663 --> 27:47.967
[SPEAKER_01]: So in the case, in FDA's eyes, then you are creating a drug.
27:48.427 --> 27:53.092
[SPEAKER_01]: So a lot of them sell, and book course them sell products using the country.
27:53.612 --> 27:58.997
[SPEAKER_01]: The lots are not supposed to use collagenese to free the cells from the matrix, and they're not supposed to expand them, right?
27:59.017 --> 28:11.348
[SPEAKER_01]: If you do any of these two things, then you're creating a drug in the FDA's eyes, and then you need to conduct an investigation in the new drug, IND study, which is why so many of these companies go overseas
28:11.328 --> 28:19.147
[SPEAKER_01]: The study is costly both in time and in money so they don't want to do that in this study That's what they did.
28:19.448 --> 28:28.830
[SPEAKER_01]: They freed the cells using collagenese and expanded them and then they used two million per kilo Treatment so two patients the first
28:28.810 --> 28:38.348
[SPEAKER_01]: Um, the first time when I did treated these patients, they give them four plasma furuses followed by, uh, retooks a mob, and then they give them IV stem cells.
28:38.368 --> 28:44.119
[SPEAKER_01]: So they were able to, uh, achieve, um, sustained remission.
28:44.099 --> 28:47.625
[SPEAKER_01]: for 12 months and 16 months, for these two patients.
28:47.946 --> 28:49.849
[SPEAKER_01]: And the second time they didn't even pre-treat them.
28:49.909 --> 28:51.272
[SPEAKER_01]: I think they were just being cautious.
28:51.312 --> 28:51.893
[SPEAKER_01]: They weren't sure.
28:52.294 --> 29:02.412
[SPEAKER_01]: And the second time they forgot about, you know, they took out the plasma ferrisis and the medication, and they both achieved improvement in their mobility and function.
29:02.392 --> 29:06.377
[SPEAKER_01]: And here's a case about sarcoidosis.
29:07.279 --> 29:14.488
[SPEAKER_01]: And so this is actually somebody that sarcoidosis for some time and tried all kinds of medications.
29:15.109 --> 29:20.957
[SPEAKER_01]: You can see the list of medications, the method of trexade, touch the cyclone, and with limited success.
29:20.937 --> 29:27.485
[SPEAKER_01]: and they were using systemic cortical steroids and they couldn't really reduce the dose.
29:27.505 --> 29:32.051
[SPEAKER_01]: So she was stabilized on the low dose steroid and methyltrexate.
29:32.071 --> 29:39.601
[SPEAKER_01]: So eight years after the diagnosis of sarcoidosis, she was diagnosed with AML, AML, leukemia.
29:40.162 --> 29:46.590
[SPEAKER_01]: And after chemotherapy, she was able to receive a local core blood
29:46.570 --> 29:48.413
[SPEAKER_01]: stem cell transplantation.
29:48.493 --> 29:56.887
[SPEAKER_01]: So five months after the transplant, she, um, to all the immune suppressive drugs were stopped and she did not have any recurrence.
29:56.907 --> 29:59.952
[SPEAKER_01]: And four years later, she still asymptomatic.
29:59.972 --> 30:08.867
[SPEAKER_01]: So that this kind of another incidental, they were treating something else and they have to give her this, um, the hematopoietics stem cell transplantation.
30:09.268 --> 30:11.852
[SPEAKER_01]: And then it cured her of sarcoidosis.
30:11.832 --> 30:23.366
[SPEAKER_01]: Now, we come to the subject of long COVID, so just kind of, you know, overview, research statistics still, there's not, you know, not that much.
30:23.426 --> 30:29.614
[SPEAKER_01]: We're still new in this, but I just want to give your overview, you know, about long COVID and then, you know, show you one case.
30:30.054 --> 30:39.426
[SPEAKER_01]: So long COVID has many names, you know, there's, I don't know why they come up with so many names, long-haul COVID, post-acute
30:39.406 --> 30:39.947
[SPEAKER_01]: P.A.
30:39.967 --> 30:42.110
[SPEAKER_01]: as C, long-term effect of COVID in any house.
30:42.130 --> 30:57.090
[SPEAKER_01]: So the long names, a definition, is that there are symptoms and conditions that continue after initial infection, and generally they don't diagnose people with long COVID until four weeks after the initial infection.
30:57.690 --> 31:06.342
[SPEAKER_01]: And the estimated incidence is about 10 to 30% of non-hospitalized cases, but 50 to 70% of a hospitalized cases.
31:06.592 --> 31:09.196
[SPEAKER_01]: and tend to 12% of vaccinated cases.
31:10.038 --> 31:24.060
[SPEAKER_01]: The prevalence as of January this year, 15% of all adults in the U.S. had reported some kind of long COVID symptom, and 6% had recurrent symptoms.
31:24.040 --> 31:37.583
[SPEAKER_01]: highest percentages in the age group of 36 to 50, and most are in the non-hospitalized patients, and they have, you know, because they had mild or acute illness, because that's the majority of the COVID-19 cases.
31:38.445 --> 31:45.677
[SPEAKER_01]: And there's even a disability, I guess, assigned to long COVID, back in July 2021.
31:45.657 --> 31:53.549
[SPEAKER_01]: So the symptoms are, you know, wide range over 200 symptoms have been identified, you know, involving many organ systems.
31:54.390 --> 32:08.712
[SPEAKER_01]: And so common, common new onset symptoms, including cardiovascular, thrombotic, cerebral vascular diseases, diabetes, type 2 diabetes, major, you know, chronic fatigue,
32:08.692 --> 32:27.966
[SPEAKER_01]: dysautonomia, including a pot syndrome, so they're general symptoms, fatigue, malaise fever, respiratory symptoms, of course, and heart symptoms, and there's neurological difficulties, digestive issues, and some other symptoms like joint pain, rash, and changing menstrual cycle.
32:27.946 --> 32:35.076
[SPEAKER_01]: And the proposed mechanism for long COVID is that there are many potential mechanisms.
32:35.396 --> 32:40.663
[SPEAKER_01]: So some think that there are reservoirs of these the virus in different tissues.
32:41.645 --> 32:47.693
[SPEAKER_01]: And other proposed mechanisms include immune dysregulation with or without.
32:47.673 --> 33:04.618
[SPEAKER_01]: reactivation of other pathogens in the body, like EVV or herpes virus, and also another proposed mechanism is that there's some kind of effect on the microbiome caused by the virus, or there's this
33:04.598 --> 33:20.678
[SPEAKER_01]: new autoimmunity that's triggered by the virus, or, you know, well, know about the clotting microvascular clotting with endothelial dysfunction, that's another mechanism, or even dysfunctional signaling in the brain stem, or vagus nerve.
33:20.858 --> 33:22.860
[SPEAKER_01]: So, MSCs for long COVID.
33:23.261 --> 33:29.388
[SPEAKER_01]: So, we've seen MSCs having therapeutic efficacy in patients with acute lung injury and ARDS.
33:30.309 --> 33:34.234
[SPEAKER_01]: What's interesting, I was very
33:34.214 --> 34:02.348
[SPEAKER_01]: In 2020, when everything was starting, already there were six studies in China using stem cells MSEs to treat patients with acute COVID and it was very encouraging, multiple studies they all showed that these people were on ventilators, they were, you know, in severe conditions within six days, these people were out of the hospital, so it was in a lot of elderly patients,
34:02.328 --> 34:09.896
[SPEAKER_01]: And then there are a lot of studies also have shown MSC benefits in improving lung function for post and lung COVID patients.
34:10.836 --> 34:14.540
[SPEAKER_01]: So these are the main mechanisms of MSC's function.
34:15.021 --> 34:19.785
[SPEAKER_01]: And a lot of times people ask me, you know, can't stand cells help me with this condition.
34:20.546 --> 34:23.349
[SPEAKER_01]: And, you know, some of the conditions are obscure.
34:23.769 --> 34:24.690
[SPEAKER_01]: So there's no studies.
34:25.111 --> 34:27.373
[SPEAKER_01]: Then I, you know,
34:27.353 --> 34:33.622
[SPEAKER_01]: So the patient down we talk about the pathophysiology, you know, what happened, what was its condition about?
34:33.662 --> 34:34.603
[SPEAKER_01]: How does it come about?
34:34.643 --> 34:37.307
[SPEAKER_01]: What was the underlying mechanism of your disease?
34:37.788 --> 34:44.196
[SPEAKER_01]: So then I see, and I look at how MSC's work, and then I'll see if we can dovetail.
34:44.657 --> 34:49.924
[SPEAKER_01]: If the way MSC works can actually target how the disease is coming about.
34:50.425 --> 34:56.854
[SPEAKER_01]: So anti-inflammatory action is a huge, one of the biggest ways that these MSC's
34:56.834 --> 34:58.926
[SPEAKER_01]: function and immune regulation.
34:58.987 --> 35:01.461
[SPEAKER_01]: So almost all
35:01.829 --> 35:06.395
[SPEAKER_01]: chronic illnesses will have inflammation and immune dysregulation as part of the picture.
35:07.296 --> 35:09.419
[SPEAKER_01]: You know, I don't care even if you had genetic diseases.
35:09.439 --> 35:12.743
[SPEAKER_01]: A lot of times the gene is not giving you the disease.
35:13.084 --> 35:16.288
[SPEAKER_01]: It's a downstream dysregulation and damage to your organs.
35:16.668 --> 35:18.170
[SPEAKER_01]: That's causing you the dysfunction.
35:18.271 --> 35:25.440
[SPEAKER_01]: So if we can look at the end organ, yes, we can, you know, there's a rescue function from these MSEs.
35:26.541 --> 35:27.803
[SPEAKER_01]: So that's the...
35:27.783 --> 35:29.626
[SPEAKER_01]: anti-apeptotic properties.
35:29.746 --> 35:44.129
[SPEAKER_01]: So on top of the immune regulation, immune modulation and anti-flemeter actions, there's also the anti-apoptotic function where the stem cells can rescue damage or semi-damage tissue and reverse the damage.
35:44.509 --> 35:46.973
[SPEAKER_01]: SEM cells can also
35:46.953 --> 35:50.359
[SPEAKER_01]: help break down scars, so anti-fibrodic properties are really important.
35:50.379 --> 35:55.889
[SPEAKER_01]: I've seen great results in my own patient with COPD and liver cirrhosis.
35:56.190 --> 36:00.658
[SPEAKER_01]: They can break down the scar tissue or even testicular nodules.
36:00.698 --> 36:02.381
[SPEAKER_01]: I've seen that disappear.
36:02.762 --> 36:06.649
[SPEAKER_01]: So the cells never fail to surprise me.
36:06.629 --> 36:26.914
[SPEAKER_01]: In the cells also have a pro-apoptotic properties in cases of senescent cells or pre-cancers or cancer's changes, so MSC's have been used for as a treatment for cancer because it does have the capability to send signals to tumors and to trigger program cell death.
36:27.134 --> 36:33.902
[SPEAKER_01]: So in the cases where they can detect cancer cells,
36:33.882 --> 36:54.321
[SPEAKER_01]: one interesting fact is that as we get older, even though we have our MSCs, our MSCs are having reduced capability of recognizing cancer, so that's why you hear this circulating fear that MSC treatments or stem cell treatment can promote cancer, and that's really
36:54.301 --> 37:02.973
[SPEAKER_01]: mostly happening when you use a person's own stem cells, because your own stem cells have lots some capabilities of recognizing cancer.
37:03.413 --> 37:24.021
[SPEAKER_01]: I call it cellular cinescence or cellular dementia, you know, it's lost certain abilities to tell that this cell doesn't belong here, whereas if you use young cells like from a local court, they are much better at detecting
37:24.001 --> 37:26.447
[SPEAKER_01]: when you age your MSC's age with you.
37:26.969 --> 37:29.836
[SPEAKER_01]: And the MSC's also have antimicrobial properties.
37:29.876 --> 37:32.944
[SPEAKER_01]: They can secret antimicrobial peptides directly.
37:32.984 --> 37:35.571
[SPEAKER_01]: They promote endogenesis.
37:35.972 --> 37:39.040
[SPEAKER_01]: So they help with vascular formation.
37:39.020 --> 37:43.287
[SPEAKER_01]: to supply the tissue with nutrients.
37:43.307 --> 37:55.208
[SPEAKER_01]: And they, of course, have this local, you know, what's called paracrin effect, conducting this local regenerative activities to tell local stem cells.
37:55.509 --> 37:57.552
[SPEAKER_01]: So so much of what MSC does,
37:57.532 --> 38:01.259
[SPEAKER_01]: is not to differentiate and become your own tissue cells.
38:01.640 --> 38:06.008
[SPEAKER_01]: It's actually to talk to your locals, you know, population that's the liver.
38:06.268 --> 38:07.751
[SPEAKER_01]: You know, I'm talking to the liver cells.
38:07.791 --> 38:09.354
[SPEAKER_01]: There are liver stem cells.
38:09.695 --> 38:15.506
[SPEAKER_01]: So MSC's is going to tell the liver stem cells is time for you to divide and replenish the tissue.
38:15.546 --> 38:17.109
[SPEAKER_01]: So that's what's happening a lot.
38:18.031 --> 38:19.894
[SPEAKER_01]: Even in musculoskeletal,
38:19.874 --> 38:25.927
[SPEAKER_01]: conditions, telling the cartilage stem cells to re-generate and start to rebuild the cartilage.
38:25.947 --> 38:30.416
[SPEAKER_01]: So that's really one of the things that I think a lot of people have the missed understanding.
38:30.436 --> 38:35.487
[SPEAKER_01]: They think these cells are just going in and start to become the cells of different tissues.
38:35.888 --> 38:38.052
[SPEAKER_01]: That has been...
38:38.032 --> 38:46.045
[SPEAKER_01]: kind of disproven, you know, in the scientific community over and over again, if you start reading articles, it just becomes, you know, it's the same, you know, it's just a repeated theme.
38:46.786 --> 38:56.361
[SPEAKER_01]: And then the mitochondria transfer, which I think is super cool, because you actually are getting fresh new mitochondria, and we all know how crucial mitochondria is for our,
38:56.341 --> 38:59.847
[SPEAKER_01]: for our cellular function and health of the body.
39:00.928 --> 39:03.693
[SPEAKER_01]: So, how do MSC's help in long COVID?
39:04.133 --> 39:18.116
[SPEAKER_01]: So, I talked about how MSC's work, so MSC's do exhibit immune-suppressive properties, so they can suppress the over-activation, the over-reaction of the immune system from the COVID-19.
39:18.156 --> 39:22.062
[SPEAKER_01]: And that's the one thing that's, you know, that's people fear as this,
39:22.042 --> 39:23.726
[SPEAKER_01]: drastic over reaction.
39:24.287 --> 39:35.414
[SPEAKER_01]: And MSEs can also locate to the inflamed lung tissue, and they can see create factors that modulate the immune system prevent the oxidative damages and fibrosis that belong.
39:35.735 --> 39:39.544
[SPEAKER_01]: So, you know, I want to dispel this myth about
39:39.524 --> 39:56.503
[SPEAKER_01]: stem cells when given IV that are trapped in the lungs, I think it's naive because later studies have shown that when you put, you know, mesenchymos stem cells into the IV route systemically.
39:56.483 --> 40:02.152
[SPEAKER_01]: Yes, initially, they're going to be in the lungs, but within three days, you can't detect them in the lungs because they're gone.
40:02.172 --> 40:14.692
[SPEAKER_01]: They're back into systemic circulation and to just look at the size of the cells and then looking at the size of the basculature in the lungs, I think it's really underestimating what these cells can do.
40:15.212 --> 40:24.567
[SPEAKER_01]: They can't squeeze through different places, so they don't just, you know, I'm this big, so I can't go anywhere.
40:24.547 --> 40:33.276
[SPEAKER_01]: travel in your capillaries, it goes to various tissues, and it travels out of your capillary and go into your neighboring tissues.
40:33.577 --> 40:35.999
[SPEAKER_01]: So they go in and out of the blood vessels.
40:36.280 --> 40:37.961
[SPEAKER_01]: So there's a lot more fluidity.
40:38.822 --> 40:46.490
[SPEAKER_01]: So I think it's time to dispel that myth that when we give some body, IV stem cells, and they're just going to all sit in the lungs.
40:46.731 --> 40:51.075
[SPEAKER_01]: If you have a lot of lung anthology and fibrosis and inflammation, yes, you bet.
40:51.095 --> 40:53.558
[SPEAKER_01]: They're going to sit there because they're really attracted to
40:53.538 --> 40:55.762
[SPEAKER_01]: to, you know, the presentation of the area.
40:56.143 --> 40:58.728
[SPEAKER_01]: But if you don't have any long problems, no, they're going to get out of there.
40:58.948 --> 41:02.735
[SPEAKER_01]: Messies also exert, at the immune modulation horizon we talked about.
41:02.836 --> 41:08.847
[SPEAKER_01]: So they exert this through the paracrin interactions, so local tissue, local signaling.
41:08.827 --> 41:10.650
[SPEAKER_01]: or even sell to cell contact.
41:10.930 --> 41:14.155
[SPEAKER_01]: The MSCs can't put it like this tentacles.
41:14.175 --> 41:19.984
[SPEAKER_01]: They can put their foot on another cell and start to talk with other cells directly.
41:20.906 --> 41:25.593
[SPEAKER_01]: They can do this exosome, extracellular vesicles.
41:25.893 --> 41:31.181
[SPEAKER_01]: So their exosomes are vesicles of certain size, only 50 to 200 microns.
41:31.422 --> 41:34.166
[SPEAKER_01]: But they're also other larger extracellular vesicles.
41:34.406 --> 41:36.449
[SPEAKER_01]: So there are a lot of these packets.
41:36.469 --> 41:37.551
[SPEAKER_01]: The cells can send out.
41:37.531 --> 41:45.367
[SPEAKER_01]: And they can also, you know, they can affect your immune system through, you know, affecting many cell types.
41:45.989 --> 41:53.464
[SPEAKER_01]: And they're capable of repairing and regenerating epithelial and endocelial tissues, and they'll be alive in the lungs.
41:53.444 --> 41:59.777
[SPEAKER_01]: MSCs can also attract functional cells to a niche in the wounded area of the lungs.
42:00.278 --> 42:04.427
[SPEAKER_01]: So that's the this I call them the conductor in the symphony regeneration.
42:04.467 --> 42:09.057
[SPEAKER_01]: They they're able to to call upon different cell types.
42:09.037 --> 42:15.889
[SPEAKER_01]: And they can replenish stem cell pool by endowing stemness.
42:15.989 --> 42:22.320
[SPEAKER_01]: This is really exciting, really fun, that they can endow differentiated cells with stemness.
42:22.701 --> 42:30.555
[SPEAKER_01]: So getting them to go back in their lineage and become more flexible and more primitive.
42:30.535 --> 42:49.270
[SPEAKER_01]: So they can transfer their own stem cell characteristics to, for example, they showed in, they can transfer that characteristic to differentiated alveoli epithelial cells in the long, long environment when it's damaged.
42:49.250 --> 42:57.238
[SPEAKER_01]: And, but MSCs can also differentiate into long tissue themselves, so that is one thing they can do.
42:57.278 --> 43:15.696
[SPEAKER_01]: They do differentiate, and they've shown MSC's differentiation, not just, you know, when people think of MSCs, yes, okay, you can show that they're MSCs by seeing whether or not they can differentiate into fat, muscles or cartilage, but that's, you know, that's just one
43:16.013 --> 43:27.164
[SPEAKER_01]: Potential, especially if you use adult MSCs, but we use younger MSCs, they have a lot more potential to differentiate into different cell types, including neurons, including liver cells.
43:27.184 --> 43:31.035
[SPEAKER_01]: And so here we see long cells, you know, epithelios tissue.
43:31.015 --> 43:42.386
[SPEAKER_01]: And MICs can also prevent certain responses that's driven by the viral injury by educating macrophages in the long environment.
43:42.807 --> 43:49.453
[SPEAKER_01]: So I guess educating them to go into a more pro-endogenic type.
43:50.094 --> 43:57.681
[SPEAKER_01]: And the macrophages will in turn, after being educated, will increase the secretion of various growth factors.
43:57.661 --> 44:00.133
[SPEAKER_01]: to promote tissue regeneration.
44:00.253 --> 44:03.047
[SPEAKER_01]: So they're telling other cells to do their work.
44:03.629 --> 44:06.523
[SPEAKER_01]: And MSC's can also adopt
44:07.027 --> 44:12.114
[SPEAKER_01]: certain types when they are exposed to inflammatory cytokines.
44:12.535 --> 44:15.198
[SPEAKER_01]: So there are two types of MSEs.
44:15.579 --> 44:16.901
[SPEAKER_01]: There's type 1 and type 2.
44:17.301 --> 44:21.367
[SPEAKER_01]: So type 2 is more untimed flammatory.
44:21.667 --> 44:29.779
[SPEAKER_01]: So when they are affected by all this inflammation, they can go into this more untimed flammatory phenotype, which is very interesting.
44:30.740 --> 44:35.667
[SPEAKER_01]: So this is one case study.
44:35.647 --> 44:50.383
[SPEAKER_01]: history of excellent health but had COVID infection in 2022 in September that lasted for 15 days right no big deal and then in October in November she noticed significant fatigue and headache that wasn't going away.
44:50.583 --> 44:59.933
[SPEAKER_01]: So what happened was that she received two weeks of IV therapy that included ozone therapy
44:59.913 --> 45:12.337
[SPEAKER_01]: and exosomium infusion, so there's a lot of study done in exosome, so this is one way the stem cells work, so it's through these exosome secretions.
45:12.698 --> 45:16.605
[SPEAKER_01]: So these exosomium infusions were given at one CC,
45:16.585 --> 45:21.898
[SPEAKER_01]: along with, you know, after ozone therapy, one C.C.
45:21.998 --> 45:25.426
[SPEAKER_01]: along with Myers and glutathione, IV push.
45:26.208 --> 45:31.220
[SPEAKER_01]: And the treatment, you know, so these were done twice a week.
45:32.202 --> 45:34.628
[SPEAKER_01]: And, and, and,
45:35.671 --> 45:45.067
[SPEAKER_01]: And the one week, first week, she was able to run errands already, and within six to eight weeks, she reached 100% recovery.
45:45.808 --> 45:49.715
[SPEAKER_01]: So two weeks of twice a week, so that means she did four sessions total.
45:50.296 --> 45:59.552
[SPEAKER_01]: And then there's some other adjunct treatment, including low dose now track zone, and nebulization of hydrogen peroxide, gluthion, and kintong water.
45:59.532 --> 46:16.140
[SPEAKER_01]: So, that's the case, you know, I welcome you, any of you have other cases, you know, any other successes, you know, I'll love to hear about that, but yeah, so this patient reached really, you know, good results with four sessions.
46:16.120 --> 46:20.707
[SPEAKER_01]: And then just last thing, I just want to talk a little bit about the tissue source.
46:21.188 --> 46:28.741
[SPEAKER_01]: You can use bone marrow or fat when local court to get stem cells, so they are all good candidates.
46:29.602 --> 46:40.660
[SPEAKER_01]: And I just want to talk about am partial to end local court stem cells because I have dumped into the subject for so long when I first started seven years ago in this whole stem cell.
46:40.640 --> 46:41.361
[SPEAKER_01]: field.
46:41.802 --> 46:43.985
[SPEAKER_01]: I just wanted to find the best source for patients.
46:44.205 --> 46:48.151
[SPEAKER_01]: I don't care what it is, I don't care what kind of training I have to do, what kind of equipment I have to acquire.
46:48.591 --> 46:50.314
[SPEAKER_01]: I just want whatever that works the best.
46:50.614 --> 47:01.270
[SPEAKER_01]: So I dealt really deep into different studies, looking at different sources, and so I have actually have, you know, I put my lecture on YouTube is called ROMC's Created Equal.
47:01.610 --> 47:03.593
[SPEAKER_01]: So I went into,
47:03.573 --> 47:05.979
[SPEAKER_01]: lots of studies comparing these tissue sources.
47:06.320 --> 47:12.394
[SPEAKER_01]: So I do believe that the local court source is superior because of many reasons I listed there.
47:12.735 --> 47:19.050
[SPEAKER_01]: So first of all, high cell viability and they have great abilities to proliferate.
47:19.030 --> 47:25.564
[SPEAKER_01]: They have anti-inflammatory, higher anti-inflammatory activities, more new regulatory capabilities.
47:26.145 --> 47:28.690
[SPEAKER_01]: They have promote more endogenesis.
47:29.432 --> 47:30.935
[SPEAKER_01]: They're more neuroprotective.
47:31.456 --> 47:33.982
[SPEAKER_01]: They can differentiate into more cell types.
47:34.382 --> 47:37.950
[SPEAKER_01]: They have longer telomeres and higher telomerase activity levels.
47:37.930 --> 47:40.354
[SPEAKER_01]: And they have more generations left.
47:40.534 --> 47:42.076
[SPEAKER_01]: They're just gonna be around longer.
47:42.116 --> 47:45.101
[SPEAKER_01]: And they have less potential to promote cancer growth.
47:45.121 --> 47:46.703
[SPEAKER_01]: So that's the one I kind of hinted at.
47:47.444 --> 47:54.395
[SPEAKER_01]: There was one study looking at fat derived MIC's versus local core derived MIC's.
47:54.415 --> 47:58.521
[SPEAKER_01]: They put these two types of MIC's next to glioblastoma.
47:58.501 --> 48:02.127
[SPEAKER_01]: So this very real-enformed brain cancer cells.
48:02.147 --> 48:08.477
[SPEAKER_01]: They put them next to these cancer cells, either in a petro-dish or on the live animal's body.
48:08.818 --> 48:16.510
[SPEAKER_01]: So in both cases, the fat derived MICs made the cancer grow more and more.
48:16.608 --> 48:21.298
[SPEAKER_01]: yet then local core derived MICs make the cancer shrink and go away.
48:21.699 --> 48:30.498
[SPEAKER_01]: So this is another reason why I think it's important as a provider, you know, I want to give people treatments not only effective, but also safe.
48:30.799 --> 48:34.667
[SPEAKER_01]: The last thing is I think as a precaution,
48:34.647 --> 48:49.192
[SPEAKER_01]: You know, probably avoiding the vaccine, you know, as first donor that have been vaccinated, you know, because there are too many unknown aspects, you know, this could be, you know, go down the whole rabbit hole about this subject.
48:49.612 --> 48:55.963
[SPEAKER_01]: But the product I use, and I insist on, will be from,
48:55.943 --> 48:57.005
[SPEAKER_01]: young healthy mothers.
48:57.485 --> 49:00.429
[SPEAKER_01]: These are all U.S. based mothers that have never been vaccinated.
49:00.510 --> 49:06.138
[SPEAKER_01]: So, yes, it's getting harder and harder, but that's one of the principles I have.
49:06.178 --> 49:11.025
[SPEAKER_01]: So, like Dr. Frank mentioned, I have booth chart biologics.
49:11.325 --> 49:12.867
[SPEAKER_01]: So, you're welcome to come talk to me.
49:13.649 --> 49:15.892
[SPEAKER_01]: But that is one philosophy I have.
49:15.912 --> 49:21.580
[SPEAKER_01]: And you know that I'm going to stick to it because I'm not willing to put that in my own body or my patient's body.
49:21.560 --> 49:24.952
[SPEAKER_01]: or anybody's body, anyone other doctors at trading.
49:24.992 --> 49:26.417
[SPEAKER_01]: So it's important to me.
49:27.622 --> 49:31.134
[SPEAKER_01]: So that's, yeah, I just think there are too many things that are unknown.
49:31.717 --> 49:32.700
[SPEAKER_01]: So that's it.
49:36.072 --> 49:38.074
[SPEAKER_01]: Thank you for listening to this episode.
49:38.595 --> 49:40.057
[SPEAKER_01]: Hope you enjoy the content.
49:40.758 --> 49:43.861
[SPEAKER_01]: And if so, please rate and follow this podcast.
49:44.182 --> 49:53.373
[SPEAKER_01]: To learn about everything I do, including my memoir Tiger of Beijing, you can go to www.doctorjoykong.com.
49:54.153 --> 49:57.598
[SPEAKER_01]: And if you like to reach me, simply send in a contact form.
49:58.378 --> 50:02.023
[SPEAKER_01]: You can also subscribe to my YouTube channel Joy Kong MD.
50:02.844 --> 50:03.885
[SPEAKER_01]: I'll see you next time.
